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ABSTRACT 
 
Pharmaceutical co-crystallisation is an alternative and potentially reliable method to 
manipulate physical properties of API‟s via supramolecular synthesis.  A number of binary 
co-crystals were synthesised using different solvents, different stoichiometric ratios (ratio of 
starting materials) and different methods of synthesis (solvent-mediated crystallisation, 
solvent-drop grinding and neat grinding), with a view to investigate solvent and 
stoichiometric effects on the materials formed. Selected α,ω-alkanedicarboxylic acids 
(HOOC-(CH2)n-COOH) were crystallised with nicotinamide for n = 0, 1, 2, 4, 5, 6, 7 and 
isonicotinamide for n = 5, 6, 7 yielding 12 new solid materials. The melting point of the 
starting materials and new products are determined and analysed, and the new crystalline 
materials characterised using NMR, FTIR, powder X-ray diffraction data (PXRD) and single 
X-ray diffraction data (SXRD). For azelaic acid : nicotinamide (1:1), structure solution was 
carried out using powder X-ray diffraction data and the direct space methods are applied 
through differential evolution (DE) approach. The crystal structure of adipic acid : 
nicotinamide (1:2) was solved using single crystal X-ray diffraction. The crystal structures of 
both, display strong O-H
….
N(pyridine), O-H
….
O=C and N-H
....
O=C intermolecular bonds. 
 
Other new materials formed were oxalic acid:nicotinamide (1:1 and 1:2), malonic acid : 
nicotinamide (1:1 and 1:2), succinic acid : nicotinamide (1:1), pimelic acid : nicotinamide 
(1:1), suberic acid : nicotinamide (1:1), azelaic acid : nicotinamide (1:1), pimelic acid : 
isonicotinamide (1:1), suberic acid : isonicotinamide (1:1 and 1:2) and azelaic acid : 
isonicotinamide (1:1), but these were not fully characterised by X-diffraction. 
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1.  INTRODUCTION 
 
1.1 Supramolecular crystalline materials and crystal engineering 
 
Over the past few decades, the „crystal engineering‟ concept has stimulated interests 
in scientists belonging to many disciplines in materials chemistry and solid state 
chemistry
2
. The concept of crystal engineering was first introduced by Pepinsky in 
1955
3, 4
. The engineering of organic crystalline structures designed on the basic 
principles of supramolecular chemistry and the application of its concepts to the 
synthesis of crystalline materials
4. The term crystal engineering can be defined as “the 
understanding of intermolecular interactions in the context of crystal packing and in 
the utilization of such understanding in the design of new solids with desired physical 
and chemical properties”5.  
 
Crystal engineering has a wide range of applications in many fields, most recently 
through the development of pharmaceutical co-crystals
6
. Pharmaceutical co-
crystallization is a method that has the potential to alter the physicochemical 
properties of an API (active pharmaceutical ingredient) without affecting its 
pharmacological properties
7
. Co-crystallization is a method of combining two or more 
“former” molecules using intermolecular interactions between the molecules without 
making or breaking covalent bonds
8
. This is often referred to as supramolecular 
synthesis.
 
Co-crystals are most commonly thought of as structurally homogenous 
crystalline materials that contain two or more neutral building blocks that are present 
in definite stoichiometric amounts.  By definition, these are materials that are 
prepared from reactants that are solids under ambient conditions (i.e. not hydrates or 
other solvates)
9
. However, the absolute definition of co-crystals is significantly still 
under debate in scientific journals and at conferences
5
. The construction of molecular 
co-crystals began as a predominantly academic interest for crystal engineers to 
investigate intermolecular interactions and intermolecular networks in families of 
molecular materials. The study of crystal behaviour enabled a wider range of 
materials to be systematically investigated as an alternative for covalent synthesis
10
. 
The results from this early work resulted in greater understanding of intermolecular 
interactions and self assembly contributing to key developments such as Etter‟s 
rules
11
.  
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Solid state synthesis of pharmaceutical materials offers great potential in the context 
of green chemistry
12
. These methods give a high yield with out using any solvent or 
little solvent with maximum prevention from the formation of by-products
13
. The 
application of these ideas has more recently been seen in solid state drug design. 
Many drug molecules are not able to show their maximum potential due to their poor 
physical properties
9
. This novel approach has been used to address poor 
physiochemical properties via supra-molecular modification. Properties such as 
bioavailability, solubility and physical stability can be tremendously improved 
through co-crystallization and the process of co-crystallization is not restricted by the 
requirement of an ionisable centre on the API molecule
8
. The stability and 
reproducibility of these crystalline forms is also more preferable than common 
amorphous solids. The development of these new co-crystalline forms is expected to 
provide fertile ground for the creation of new patents and intellectual property
14
. 
 
A proper understanding of the solid state properties of crystal and amorphous forms is 
important in the development of pharmaceutical co-crystals
7
. Crystallization of two or 
more organic compounds with appropriate (donor and acceptor) functional groups 
using a solvent can result in the formation of co-crystals, ionic salts, solvates, hydrates 
or polymorphs. There is considerable interest in the pharmaceutical industry to 
identify all possible solid state forms of an API as their properties often vary from one 
form to another subsequently showing effect on physical properties and medicinal 
activity
15
. 
 
The phenomenon of polymorphism was recognised by Mitscherlich in 1822. The 
Aarone‟s definition of polymorphism says „a solid crystalline phase of a given 
compound in the solid state‟ and this definition is appropriate in the context of 
pharmaceutical materials manifest themselves in to multiple modes of self assembly
15, 
16
.
 
A good co-crystallizing agent would form heteromeric intermolecular interactions 
with good flexibility towards different unit cell formations within the co-crystal
17
. 
Synthon flexibility and polymorphic behaviour are the essential qualities for a co-
crystallizing agent. The ability of forming fruitful and multiple (different) 
intermolecular interactions between the molecules can be considered as synthon 
flexibility. The ability of H-bonding between molecules depends on donor and 
acceptor functional groups in the molecules
17
.  
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1.2 Characterisation of organic materials from X-ray diffraction methods 
(PXRD and SXRD) 
 
Crystal structure determination of organic materials from Powder X-ray diffraction 
(PXRD) data is feasible due to the recent advancements of 20
th
 century in ab initio 
crystal structure determination studies, software data analysis and direct space 
methods. The Single X-ray diffraction (SXRD) technique is a powerful tool for 
determination of crystal structures and the structural information obtained from 
SXRD would be more accurate when compared to information obtains from PXRD
18
.  
But because of limitations towards microcrystalline materials and quality of 
crystalline materials, crystal structure determination from PXRD is a considered as 
potential method for structural characterisation despite of materials size and quality
13
. 
 
PXRD is most commonly used in the qualitative identification of materials for its 
property of having a unique characteristic finger print for each material. The aim of 
the crystal structure determination from either SXRD or PXRD is to establish the 
distribution of electron density in the unit cell and this requires the extraction of 
information in the form of diffraction intensities from the experimental data. The data 
obtained from PXRD and SXRD contains same structure information but in SXRD, 
the diffraction intensities are distributed in three dimensional space and in latter, the 
three dimensional data is compressed to one dimensional. As a result the information 
on individual diffraction intensities is obscured and hence the compressed one 
dimensional data would lose phase information
19
. 
 
The electron density within a unit cell is the reverse Fourier transform (FT
-1
) of the 
diffraction pattern. The diffraction pattern from a crystal would be obtained from the 
below expression (see equation 1.2.6.1). The inverse of the above expression gives 
latter expression (see equation 1.2.6.2) for the electron density within the unit cell. 
The structure factors can be obtained from the diffraction peak intensities, but data for 
α(S) cannot be obtained. This is known as the Phase Problem. The direct crystal 
structure determination would be possible if both amplitude and phase information 
can be obtained from the powder X-ray diffraction data
20
. 
 
F(s) = │F(S)│exp[2πiα(s)] = ∫ρ(r)exp(2πis.r)dr                                  (1.2.6.1) 
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ρ(r) = 1/v ∑│F(S)│exp[α(S)-2Πis.r]                                  (1.2.6.2) 
 
Where  F(s)  =  Fourier coefficient 
  ρ(r) = electron density function 
  v = volume of fundamental parallelepiped 
 
The crystal structure determination from PXRD mainly involves three steps. The first 
step is indexing X-ray diffraction patterns to obtain lattice parameters, crystal system 
and space group. The success rate of the whole method mainly depends on the first 
step. The second step is the application of direct space methods to obtain approximate 
structure solution for the crystal structure
13
. Differential search algorithms have been 
applied for the structural solutions throughout the current project. This optimisation 
technique is implemented based on the Darwinian principles of natural evolution 
which involves the processes of mating, mutation and natural selection. The last step 
involves refinement of structure solution using Rietveld refinement to obtain accurate 
crystal structure. The refinement of structure involves subjecting the molecular 
structural model to various bond lengths and bond angle restraints
18
. 
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1.3 AIMS OF PROJECT 
 
The aim of the current project is to synthesize binary co-crystals using solvent 
mediated crystallisation and solvent drop grinding methods using different solvents 
(methanol and ethanol) and stoichiometric ratios. The former molecules chosen for 
study have complementary functional groups (donor and acceptor) that can form 
potential supra-molecular bonds in the crystallisation process. Pyridine ring and amide 
functional groups on nicotinamide and isonicotinamide can form hydrogen bonds with 
carboxylic acid functional groups on di-carboxylic acids producing co-crystals or 
potentially salts. The crystal structures of any new materials will be solved using 
powder X-ray diffraction and Single crystal X-ray diffraction methods by the 
application of direct space and direct methods respectively. In PXRD, crystal 
structures are solved using differential evolution and Rietveld refinement techniques. 
This project also aims to investigate the potential effects of the variation of methods 
of synthesis, solvents and stoichiometric ratios on the cocrystallization behaviour and 
crystal structure of the resulting materials. 
 
SPECIFIC AIMS: 
 
 The synthesis of cocrystalline molecular materials of nicotinamide and 
isonicotinamide with a series of selected α,ω–alkanedicarboxylic acids: 
 Oxalic acid 
 Malonic acid 
 Succinic acid 
 Adipic acid 
 Pimelic acid 
 Suberic acid 
 Azelaic acid 
 Attempted synthesis of these materials by solvent mediated crystallization 
from ethanol and methanol under ambient conditions and from solvent drop 
grinding. 
 Co-crystallization of from different starting stoichiometric ratios. 
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 Characterization using powder X-ray diffraction data to conform the formation 
of new material. 
 Characterization of new materials using NMR (to identify stoichiometries) and 
IR techniques (co-crystal formation). 
 Analysis of melting points of new materials with respect to the starting 
materials. 
 Crystal structure determination using single X-ray diffraction and powder X-
ray diffraction methods. 
 Discussion and analysis of new structures relative to each other and other 
previously published structures. 
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2.  MATERIALS UNDER INVESTIGATION 
 
 
 
 
 
 
 
 
 
 
(a)                                                       
 
 
 
 
 
 
 
 
 
(b)    
 
Figure 2.1: Molecularstructures of (a) Nicotinamide and (b) Isonicotinamide. 
 
Nicotinamide and isonicotinamide (see figure 2.1) were used commonly throughout 
the project in crystallisation with dicarboxylic acids in the synthesis of binary co-
crystals. The structures of the two molecules are structurally similar but differ in 
position of the N atom in the pyridine rings. Nicotinamide is also known as vitamin 
B3. These two „former‟ molecules were investigated in combination with the α,ω-
dicarboxylic acids shown in figure 2.2 with the aim of investigating and comparing 
the structural behaviour of nicotinamide and isonicotinamide by study of the crystal 
behaviour and properties of materials formed
6, 21
. The alternation in melting points 
with increase in carbon chain in the dicarboxylic acids adducts was also investigated. 
N
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H
H
H
H
H
H
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H
H
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H
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Carboxylic acids are known to act as good electron acceptors and electron donors and 
they often participate well in supramolecular reactions.  Carboxylic acids also come 
under the category of GRAS (Generally Recognised as Safe) as defined by the FDA 
(the Federal Drug Agency)
22
 and hence are potential co-crystal formers for 
combination with an API in pharmaceutical materials. 
 
Figure 2.2: 
       
 
 
 
(a) Molecular structure of oxalic acid 
 
 
 
 
(b) Molecular structure of malonic acid 
 
 
 
 
(c) Molecular structure of succinic acid    
 
 
 
  
(d) Molecular structure of adipic acid 
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(e) Molecular structure of pimelic acid 
 
 
 
 
 
 
 
 
(f) Molecular structure of suberic acid 
 
 
 
 
 
 
 
(g) Molecular structure of azelaic acid 
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2.1 Synthon flexibility 
 
Crystal engineering of organic materials relies on the supramolecular building of 
crystalline solids based on the interaction of functional groups point of view. For the 
study of these crystalline materials, it is important to have a knowledge and 
understanding of intermolecular interactions between various functional groups
8, 23
.  
Functional groups such as carboxylic acids and amides are known to form robust 
synthons in the absence of other strong hydrogen bonding functional groups. The 
change in a common hydrogen bonding pattern of a particular functional groups can 
be observed, due to the presence of other functional groups in a molecule. An 
understanding of these interference effects is very important in crystal engineering 
and can be used in the design of preformed architectures. The factors to be considered 
are the matching of the strengths of donor and acceptor, cooperative effects of a 
synthon, balance between the number of donors and acceptor and solvation effects
24
. 
 
The effective and rapid synthesis of new materials is the main attraction in 
supramolecular chemistry with the ability to change physical properties e.g., 
solubility, crystal morphology, mechanical stability. Molecules with reliable 
functional groups are ideal candidates to engage in supramolecular heteromeric 
intermolecular interactions leading to successful co-crystallisation. This project deals 
with nicotinamide and alkyl dicarboxylic acid molecules with complementary 
functional groups (carboxylic acid, amide and pyridine N) and investigates the 
preferred formation of homomeric motifs or heteromeric synthons. 
 
The presence of two carboxylic acid groups in the diacids potentially allows 
formation of products with different stoichiometric ratios of acid-amide components. 
By using a series of alkyl dicarboxylic acids, the effect of increased hydrophobicity 
and flexibility with systematic increase in carbon chain length can be related to any 
variation of stoichiometry in the resulting materials. These molecules would form 
synthons N
…
H-O, N-H
…
O, C-H
…
O and O-H
…
O intermolecular bonds when they are 
crystallised with nicotinamide and isonicotinamide molecules with potential pyridine 
and amide functional groups. There has been significant research going on co-
crystallisation of dicarboxlic acids and APIs with complementary functional groups 
attracting pharmaceutical industries to rely on such molecules as potential 
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supramolecular reagents for crystallisation of pharmaceutical materials. Crystal 
structures of molecules with functional groups similar to isonicotinamide and 
dicarboxylic acids tend to display a few common intermolecular interactions, hence 
various combinations can be expected when such molecules are engaged for co-
crystallisation (see figure 1.2.6.1). 
 
Figure 2.1.1: Schematic diagram showing potential supra-molecular synthons in co-
crystals formed by isonicotinamide and di-carboxylic acids. 
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An important consideration while selecting organic molecules for potential co-
crystallisation is to choose a crystallising agent that displays polymorphism. 
Polymorphic materials have the potential ability to form heteromeric intermolecular 
interactions, with the target molecule rather than homomeric interactions showing 
degree of structure flexibility. Aakeröy identified isonicotinamide, 2-amino-3-
nitropyridine, 4-chlorobenzamide and maleic hydrizide as potential polymorphic 
molecules to form multiple hydrogen bonds and heteromeric synthons (see figures 
1.2.6.2 (a-d))
17
.  
N
O NH2
       N NH2
N
+
O
-
O
          Cl
O NH2
           
N
N
H
O
OH  
(a)                   (b)                                 (c)                            (d) 
 
Figure 2.1.2:  Molecules capable of forming a variety of hydrogen bonded synthons : 
(a) isonicotinamide, (b) 2-amino-3-nitropyridine, (c) 4-chlorobenzamide and (d) 
maleic hydrazide. 
 
One area of current interest in crystal engineering of organic materials is the synthesis 
of co-crystals using supramolecular reactions by establishing preferential hydrogen 
bonds. The formation of hydrogen bond interactions between molecules follows a 
hierarchical order; best donor to best acceptor; second best donor to second best 
acceptor
11
. In the example below, the best donor (carboxylic acid) and the best 
acceptor (heterocyclic ring) form a heteromeric motif while a homomeric motif is 
formed between the amide moieties (second best donors and acceptors) (see figure 
1.2.6.3). 
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Figure 2.1.3: Carboxylic acid : isonicotinamide (1:1) co-crystal showing different 
intermolecular interactions between the molecules. 
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Aakeröy and co-workers
8
 and Nangia
24
 and co-workers have been amongst groups 
that have been successful in the exploitation of Etter's rule to design binary complexes 
of nicotinamide and isonicotinamide co-crystals with carboxylic acids
8
.  In these 
structures, carboxylic acid interacts as strong proton donor and pyridine as strong 
acceptor. All the structures indicate that the acid-pyridine synthon is favoured over 
amide-acid and amide-amide motifs according to the hierarchy of the interactions
17
. 
However, there are several reports indicating that the result of crystallization 
experiments does not necessarily obey the hierarchy of interactions or the 
complementarities of the components.  The final outcome of the crystallization 
depends on several other factors such as solvent, dilution, rate of evaporation and 
solvent of the components
23
. 
 
Analysis number of a crystal structures (and their intermolecular interactions) in the 
CSD through the crystallisation of di-carboxylic acids with heterocyclic N compounds 
allows for the prediction of a few common synthons and motifs based on the nature 
and behaviour of functional groups in the molecular structures (see figure 1.2.6.14). 
The acid – pyridine heteromeric synthon is a common intermolecular bond present in 
all crystal structures of this type (see figures 1.2.6.5-1.2.6.13). Hence, it is strong 
intermolecular bond among synthons formed by molecules with pyridine, carboxylic 
acid and amide functional groups (1.2.6.14 (a)). Amide – amide homomeric motifs are 
found in crystal structures with components in 1:2 stoichiometric ratios (1.2.6.14 (g)). 
Similarly, acid – amide heteromeric synthons are only observed in 1:1 crystal 
structures (1.2.6.14 (c)). No specific sequence was found with the presence of other 
synthons (1.2.6.14 (b – h)). Weak intermolecular bonds (1.2.6.14 (e, f)) are observed 
in all crystal structures as reinforcing on binding links often between the chains and 
ribbons found in these structures. 
 
For effective and promising co-crystallisation, the former molecules should have 
potential hydrogen bond donor and acceptor groups with desired pKa values for the 
formation of supramolecular bonds between the molecules. For the formation of a 
salt, a difference of pKa ≥ 3 is desirable between an acid and a base. The equilibrium 
pKa values between former molecules is considered as an important criterion for the 
formation of a co-crystal. Almarsson and Zaworotko
25
 illustrated salt and a co-crystal 
formation between saccharin and different former molecules with a wide range of 
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functional groups, and observed that the molecules with pKa difference > 3 form salts 
(see figure 1.2.6.4) whereas structures with equilibrium pKa values formed co-
crystals.  
 
(a) 
S
-
N
+
O
+
O
O
N
+
O
CH3
CH3
H
-
O
CH3
H
-
     (b)  
Figure 2.1.4: (a)Venlafaxine saccharinate showing N
(+)
-H
…
N and O-H
…
O=C 
interactions between the two components and (b) Carbamazepine isonicotinamide 
showing N-H
....
O interactions between the two components. 
The alternation in structural behaviour and properties with change in the number of 
methylene groups in α,ω-alkanedicarboxylic acids has also attracted attention for 
further investigation towards an understanding behaviour of such molecules. 
Vishweshwar et al. correlated the structures of α,ω-alkanedicarboxylic acids with the 
properties of the relative isonicotinamide co-crystals. They investigated co-crystals 
synthesized through the crystallisation of oxalic acid, malonic acid, succinic acid, 
glutaric acid and adipic acid with isonicotinamide.  All products were obtained in a 
1:2 stoichiometric ratio. Co-crystallisation of glutaric acid and adipic acid with 
isonicotinamide formed new materials in both 1:1 and 1:2 stoichiometric ratios
21
. 
Polymorphism has also been reported in the case of oxalic acid:isonicotinamide (1:2); 
the significant difference between the crystal structures of these polymorphs is due to 
differing conformation (cis and trans) of the oxalic acid molecule
26
. Fumaric acid is 
also of interest with a molecular structure similar to that of succinic acid
27
. Other 
materials that have been co-crystallised  with dicarboxylic acids include cyclic amides 
2-pyrrolidinone, 2-imidazolidinone, benzamide etc
21, 22
. 
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In the oxalic acid : isonicotinamide (1:2) form I and form II co-crystals, the crystal 
structure is stabilized by O-H
.…
N(heterocyclic) interactions, centrosymmetric 
homomeric amide motifs formed through N-H
….
O=C (pyridine) interactions, and C-
H
….
O=C (carbonyl) and N-H
….
O=C(carbonyl) intermolecular interactions. Although 
the stable conformation of the oxalic acid molecule is anti conformation (see figure 
1.2.6.6), the oxalic acid molecule in one of the polymorphic forms exits in the syn 
conformation (see figure 1.2.6.5). 
 
Figure 2.1.5: A view of the crystal structure of oxalic acid : isonicotinamide (1:2) 
form I co-crystal showing intermolecular interactions. 
           
Figure 2.1.6: A view of the crystal structure of oxalic acid : isonicotinamide (1:2) 
form II co-crystal showing intermolecular. 
The malonic acid : isonicotinamide (1:2) adduct is stabilized by different 
intermolecular bonds between the molecules. The tapes in the crystal structure are 
formed by O-H
….
N(heterocyclic) intermolecular interactions and these tapes are 
combined by (methylene)C-H
….
O(carbonyl) intermolecular bonds. There are also 
weak intermolecular bonds (pyridine)C-H
….
O=C (blue colour dotted) that reinforce 
the tapes shown in figure 1.2.6.7) along with the strong former intermolecular bonds. 
RAJA SEKHAR VOGURI                  MATERIALS UNDER INVESTIGATION 
_____________________________________________________________________ 
 16 
 
Figure 2.1.7: A view of the crystal structure of malonic acid : isonicotinamide (1:2) 
co-crystal showing intermolecular interactions. 
The succinic acid : isonicotinamide (1:2) co-crystal is also stabilized through O-
H
…
N(heterocyclic) heteromeric synthons, homomeric centrosymmetric motifs formed 
through N-H
…
O=C intermolecular bonds and N-H
….
O=C linking these tapes together. 
Along with strong intermolecular bonds, there is again a number of weak 
intermolecular bonds reinforcing the structure (blue colour dotted intermolecular 
bonds shown in figure 1.2.6.8). 
 
Figure 2.1.8: A view of the crystal structure of succinic acid : isonicotinamide (1:2) 
co-crystal showing intermolecular interactions. 
The glutaric acid:isonicotinamide (1:1 and 1:2) co-crystals are stabilized through 
heteromeric synthons O-H
…
N(pyridine), homomeric centrosymmetric motifs formed 
through N-H
…
O=C intermolecular bonds, (pyridine)C-H
….
O=C, N-H
…
O(COH) and 
N-H
….
O=C
 
supramolecular bonds (see figures 1.2.6.9 and 1.2.6.10). The significant 
difference between the crystal structures of two stoichiometric ratios can be seen in 
the formation of amide dimers in 1:2 and heteromeric dimers (acid:amide) in 1:1. The 
molecular ribbons in 1:1 were linked by intermolecular bonds between carbonyl O 
and amide H. In 1:2, these ribbons are combined by intermolecular bonds between 
hydroxyl O and amide H. 
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Figure 2.1.9: A view of the crystal structure of glutaric : isonicotinamide (1:1) co-
crystal showing intermolecular interactions. 
 
Figure 2.1.10: A view of the crystal structure of glutaric acid : isonicotinamide (1:2) 
co-crystal showing intermolecular interactions. 
The co-crystals resulting from the crystallisation of adipic acid and isonicotinamide 
were also obtained in both 1:1 and 1:2 stoichiometric ratios and were stabilized 
through heteromeric synthons O-H
.…
N(heterocyclic), homomeric centrosymmetric 
motifs  and heteromeric synthons formed through N-H
…
O=C synthons, (pyridine)C-
H
….
O=C and methylene C(H)-H
….
O=C intermolecular bonds (see figures 1.2.6.11 and 
1.2.6.13). The adipic acid in folded S-conformation in the crystal structure (1:1) is 
stabilized due to C-H
….
O=C intramolecular bonds within the molecule (see figures 
and 1.2.6.13). Along strong intermolecular bonds, there would be the possibility for 
the existence of weak (pyridine) C-H
….
O=C intermolecular bonds (blue colour dotted 
intermolecular bonds shown in figure 1.2.6.12). Similar strong intermolecular bonds 
can be observed in co-crystals formed through the crystallisation of oxalic acid, 
malonic acid, succinic acid, glutaric acid and adipic acid with isonicotinamide in 1:1 
and 1:2 stoichiometric ratios. The molecular frameworks in 1:1 co-crystals are 
observed with heteromeric dimers (acid : amide) and 1:2 co-crystals with homomeric 
amide dimers. The common strong intermolecular bond appears in both stoichiometric 
co-crystals is O-H---N(pyridine). 
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Figure 2.1.11: A view of the crystal structure of adipic acid : isonicotinamide (1:2) 
co-crystal showing intermolecular interactions. 
 
 
Figure 2.1.12: A view of the crystal structure of adipic acid : isonicotinamide (1:1) 
co-crystal showing intermolecular interactions. 
 
Figure 2.1.13: Folded S-conformer of adipic acid in adipic acid:isonicotinamide (1:2) 
co-crystal. The intramolecular C-H
….
O hydrogen bonds is shown with bold dash lines.  
 
The summarization of a number of crystal structures (and their intermolecular 
interactions) in the CSD through the crystallisation of diacids with heterocyclic 
compounds implies possibility for the prediction of few common synthons and motifs 
relying on nature and behaviour of functional groups in the molecular structures. 
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2.2 Methods and Materials 
 
Co-crystals are formed if different molecules with complementary functional groups 
form hydrogen bonds that are thermodynamically more favourable than those between 
like molecules of either component
28
. Individual components are obtained after 
crystallisation if the formation of these alternative bonding networks is not 
energetically favoured. Depending upon the composition of the resulting crystal 
structures, co-crystals can be further classified as polymorphic, solvated and 
hydrates
8
. The most energetically favoured crystal structures obtained through 
crystallisation can also differ by inducing different stoichiometries (ratio of starting 
materials), solvents or different crystallisation methods. The existence of more than 
one new co-crystalline material with the same composition or stoichiometric ratio is 
also polymorphism
12, 15
. Inclusion of one or more solvent molecule results in a 
solvated co-crystal. Similarly, inclusion of one or more water molecule results in a 
hydrate
29
.  
 
2.2.1 Solvent-mediated crystallization 
 
The most common approach to the synthesis of co-crystals is solvent-mediated 
crystallisation in which two or more suspensions are obtained by dissolving 
stoichiometric amounts of starting materials in a solvent, mixing these together, and 
storage under optimized temperatures for co-crystallisation. The formation of the 
product depends on the relative solubility of the starting materials, experimental 
temperature and functional groups in the former molecules. The formation of a co-
crystalline product can vary with concentrations of starting materials (stoichiometric 
ratios) and solvents and most likely a new co-crystalline form would be obtained 
unless co-crystal form is more stable than individual pure forms with minimal 
solubility. Although, sublimation, growth from the melt, sonic slurry and the grinding 
of solid formers in a ball mill are also suitable methodologies for the synthesis of co-
crystals, solvent mediated transformation is simple, flexible and adaptable with many 
possible configurations for co-crystal synthesis
4, 30
. 
 
An important goal of solid-state pharmaceutical development is to optimize drug 
solubility while preserving drug activity. Co-crystals have emerged as a promising 
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means to modify solubility, dissolution, and other physicochemical properties of drug 
substances. Solubility is a complex parameter and in this work effects both this 
effectiveness of the co-crystal formulation in terms of drug solubility and 
bioavailability and in the initial synthesis of the co-crystal itself. Solubility has been 
cited to depend on the enthalpy of fusion, temperature of the solvent, melting point of 
the solid, hydrogen bonding in the solid and solvent, and other polar and non-polar 
forces in the solvent and the solute. It has long been known that hydrogen bonding 
networks, along with other intermolecular forces, are known to contribute to effect 
physical properties of solids
5, 30
. When two or more suspensions are obtained by the 
dissolution of stoichiometric amounts of starting materials in a solvent and mixed 
together, and storage under optimized temperatures for co-crystallisation, the 
concentration of solution slowly increases. At a certain concentration, crystallization 
would start the formation co-crystals, leading to equilibrium point where three forms 
(L+A, L+B, L+AB) coexist; where L is liquid, A and B are the initial solid 
components and AB is the co-crystal form. Phase solubility and triangular phase 
diagrams are used to represent the solubility and stability of co-crystals
3
 (see figure 
1.2.1) and can be used to optimise conditions for co-crystal formation rather than 
recrystallisation of the individual components
31
. 
 
Figure 1.2.1(a) shows a schematic triangular phase diagram at constant temperature 
for an API A, coformer component B, and solvent in which A is more soluble than B. 
At low concentrations of A and B in region L, a clear liquid exists. Overall 
compositions in the L+A, L+B, or L+AB region eventually equilibrate to comprise a 
liquid with a composition on the solubility line of A, B or AB respectively. Between 
these regions, mixtures of three phases can coexist (L+A+AB and L+B+AB). A 
composition in these regions eventually equilibrates to a liquid with a composition of 
the three-phase equilibrium point (the intercept of the pure component solubility line 
and co-crystal solubility line), and a solid mixture of AB crystals and A crystals (in 
the L+AB+A region) or AB crystals and B crystals (in the L+AB+B region). 
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(a)  (b)  
Figure 2.2.1.1: (a) A schematic ternary phase diagram for a highly soluble co-crystal 
system in solution at constant temperature. (b) A schematic phase diagram for slightly 
soluble components and co-crystal
30
. 
 
 Figure (b) represents an alternative schematic phase diagram in which both 
components are slightly soluble. It shows a horizontal line for the coformer 
component solubility xB*, a vertical line for the API solubility xA*, and a curved line 
for the co-crystal solubility (xA.xB)*. Here it is assumed are that the solubility of each 
component is not affected by the presence of the other, except where a co-crystal is 
formed, and the solubility product (xA.xB)* of the co-crystal at a certain temperature is 
essentially constant. Both phase diagrams show a specific region (L+AB), in which 
only the co-crystal is in stable equilibrium with the solution. Both components A and 
B are needed in specific concentrations, defined by the boundaries of the (L+AB) 
region, in order for the co-crystal to be more stable than the pure component crystals 
and to be the sole solid phase present after equilibration. 
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A solution with overall composition inside the co-crystal region at the specified 
temperature will eventually co-crystallize as this is the most stable solid phase in the 
co-crystal region. Similarly, a suspension prepared from pure components with an 
overall composition inside the co-crystal region will also eventually co-crystallize. 
The use of such phase diagrams is a key tool in co-crystal synthesis. 
 
2.2.2 Solvent drop grinding or liquid assisted grinding (SDG) 
 
One approach used to circumvent unfavourable solubility issues that are often 
highlighted in the phase diagram as in section 1.2.1 is the use of mechanochemical 
methods. Binary co-crystals can be synthesized either by neat grinding of the two 
starting materials or in the presence of small amount of liquid phase or solvent (liquid 
assisted grinding or solvent drop grinding). SDG is a new promising and green 
process to accelerate the synthesis of co-crystals by grinding of starting materials with 
the addition of little solvent 
32, 33
. It is anticipated that this approach will open new 
avenues in both the synthesis and characterisation of co-crystals, despite the 
limitations to characterize many materials obtained using this method by single-
crystal X-ray diffraction. With this limitation in mind, this project also aims to explore 
the characterization of binary co-crystals made in this way by determination of crystal 
structures from PXRD (Powder X-ray diffraction data)
2, 29, 34
. This synthetic approach 
has the potential to produce co-crystals of new stoichiometry or a solvent-free adduct 
that cannot be prepared by traditional crystallisation approaches
33
. 
 
Co-crystals are often prepared by a traditional solvent mediated crystallisation 
approach and there are a number of reasons for the popularity of this approach. 
Solution crystallisation can yield single crystals with sufficient size, from which one 
may easily evaluate the crystal structure, crystal habit and surface features. However, 
there are several drawbacks to the solution crystallisation approach. The solubility of 
the starting components is one, as a suitable solvent for all starting materials must be 
identified before co-crystallisation may occur. Unexpected solvate formation and the 
large quantities of solvents necessary to prepare co-crystals in this way may also pose 
problems in forming desired the co-crystalline materials.  
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2.2.3 Salts and co-crystals 
 
When an acid and a base are crystallized together using an appropriate solvent, the 
outcome would be salt or a co-crystal. The APIs having ionisable functional groups 
when crystallized with former molecules with complementary functional groups 
would form salts rather than co-crystals with non-covalent intermolecular bonds. The 
strategy behind the formation of a salt is an acid, a base and one or more solvents
9
. A 
salt is formed by transfer of proton from the acid to a base i.e., simple proton transfer 
between a donor and an acceptor and co-crystals are obtained through the formation 
of strong hydrogen bonding or non-covalent intermolecular bonds between a donor 
and an acceptor. For example, the synthons formed with as O−H···N intermolecular 
interaction is a co-crystal and one with O
-
−H···N
+
 a salt (see figure 1.2.3.1). To 
determine the general differences between the reliability and predictability of the 
physical properties of salt and co-crystal forms, Aakeröy selected 85 crystal structures 
of which 61 are co-crystals and 24 are salts. (This study was confined to 
pyridine/benzoic acid and benzoate fragments). 58 out of 61 co-crystals (no solvates) 
and stoichiometrics are expected. 24 out of 85 structures were found to be salts 
resulting from a proton transfer from the acid to a nitrogen atom in an N-heterocyclic. 
Thirteen out of 24 compounds displayed the expected stoichiometry and primary 
intermolecular interactions. 9 out of 24 salts displayed an unpredictable stoichiometry 
resulting from the incorporation of carboxylic acid into the lattice. 
 
 
 
 
(a) 
 
 
 
 
(b) 
Figure 2.2.3.1: Formation of a supramolecular adduct and as ionised adduct of 
benzoic acid : dichloropyridine in (a) co-crystal and (b) salt forms. 
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Co-crystals and salts show dramatic difference in terms of crystal behaviour and 
physical properties. The molecules with ionisable centres can form salts with 
appropriate counter ions. Varying the salt forms changes properties such as solubility 
and dissociation rates. A salt form involves a three component system of an acid, base 
and one or more solvents. A salt is formed by transfer of a proton from an acid to a 
base and it requires atleast 3 pKa units between them. In the example below (see 
figure 1.2.3.2), the carboxylate moiety is not readily satisfied with a single hydrogen 
donor, so, it tends to react further with other neutral carboxylic acid molecule. The 
neutral carboxylic acid is less powerful to bring another carboxylic acid. This example 
shows that the absence of functional groups such as amides in the starting components 
may lead to unexpected lattices. Such groups are capable of adding extra hydrogen 
donors.  
 
N
N
H
-
CH
3
CH
3
OO
CH3
CH3
CH3
2+
O
O
H-
CH3
CH3
CH3
CH3
CH3
 
Figure 2.2.3.2:  Example showing both proton transfer and supra-molecular synthons 
in 3-(4-pyridinium)-pyrazolepentamethylbenzoate pentamethyl benzoate : pentamethyl          
benzoic acid. 
 
 
2.2.4 Co-crystal Solvates 
 
The term „solvate‟ defines the inclusion of one or more solvent molecules in the 
crystal structures and is sometimes called solvatomorphism. Solvatomorphism can be 
defined as the existence of a solvates with different crystal structures and same 
elemental composition along with inclusion of one or more solvent molecules in the 
crystal structure
35
. 
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Solvents play a major role in the successful crystallization of starting materials (pure 
forms) to obtain different crystal structures. New materials formed through solvent 
mediated crystallisation can be either co-crystal, solvates, hydrates or salts, however 
the presence of solvent in many crystal structures can be considered as an advantage. 
Large crystal structures with empty cavities are often unstable and inclusion of 
solvent molecules can improve the stability of such crystal structures
35
. 
 
Solvent molecules play a role in the stabilization of crystal structures in different 
ways; the molecules can participate in hydrogen bonding as an integral part of the 
crystal structure network or as a space filler without strong interaction with other 
molecules in the crystal structure. Solvent molecules having ketone, hydroxyl and 
alkyl groups can act as bridges between polar and non polar regions in the crystal 
structures. It is interesting to note from the figures below that the proportion of 
solvates in the Cambridge Structural Database has dramatically increased in recent 
years (see charts 1.2.4.1 and 1.2.4.2). 
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Chart 2.2.4.1: The percentage of published crystal structures which contain co-
crystallized organic solvent molecules
36
. 
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Chart 2.2.4.2: The percentage of solvates in which there are two or more different 
types of solvent molecules
36
. 
 
2.2.5 Co-crystal hydrates 
  
Co-crystalline materials formed with inclusion of water molecules in their crystal 
structures comes under the category of co-crystal hydrates. These materials provide an 
alternative route to achieve high stability from high humidity conditions. In a recent 
paper
37
, it was reported that neat grinding using the hydrated form of reactants and 
liquid drop grinding are proven to be more efficient compared to solvent mediated 
crystallization
37
.  
 
The properties of co-crystal hydrates are important for the API‟s which are very hard 
to obtain in anhydrous form. Different crystal structures were obtained from neat 
grinding and solvent drop grinding of theophylline and citric acid materials. 
Anhydrate co-crystal was obtained from neat grinding of citric acid and co-crystal 
hydrate from liquid drop grinding
29
. Theophylline:citric acid hydrate was obtained 
through solvent drop grinding method using water as solvent. The crystal structure is 
abanded with four membered centrosymmetric rings bonded together by O−H···O 
hydrogen bonds. The theophylline : citric acid hydrate was formed with O-H---N and 
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N-H---O intermolecular bonds formed with consecutive layers of theophylline and 
layers of citric acid and water (see figure 2.2.5.1). From chart 2.2.5.1, it is evident that 
there was a high initial interest in co-crystal hydrates in 1950s and gradual decrease 
over the following years. 
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Figure 2.2.5.1:  Theophylline:citric acid hydrate showing supramolecular adducts. 
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Chart 2.2.5.1: The percentage (in %) of the published co-crystal hydrates
36
. 
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3. EXPERIMENTAL 
 
3.1 Solution mediated crystallization 
 
0.5 g of nicotinamide or isonicotinamide and the corresponding molar ratio of the 
dicarboxylic acid were dissolved individually in two conical flasks in the chosen 10ml 
solvent (methanol and ethanol) at room temperature. The solutions were stirred and 
warmed (if necessary) until the starting materials were completely dissolved. The 
solutions were filtered to avoid the inclusion of undissolved starting materials in the 
filtrate. The filtered solutions were mixed and left on the bench for crystallization 
under room temperature. The material obtained from crystallization was filtered and 
dried under suction. This experimental method was repeated using different solvents 
(methanol and ethanol) and stoichiometric starting ratios (1:1, 1:2 and 2:1). 
 
3.2 Solvent drop grinding 
 
0.25g of nicotinamide and isonicotinamide and the corresponding molar ratio of the 
dicarboxylic acid were ground together after adding a few drops of solvent (methanol 
and ethanol). The mixture was ground for 30 minutes at room temperature. 
 
3.3 Powder X-ray diffraction data 
 
The crystalline samples were ground and mounted in a flat disc of approximately 
10mm diameter between transparent polyethylene tape. All data were collected at 
room temperature using a Bruker AXS D5000 or a Bruker D8 high resolution X-ray 
powder diffractometer with Ge-monochromated CuKα1 radiation with wavelength of 
λ=1.54056Å. Powder X-ray diffraction data were recorded between 5°<2θ<60° or 
5°<2θ<90° for 30 minutes, for one hour or for 10 hours depending on the level of data 
analysis required. The step size was 0.0202°. The shorter data range was used to 
identify new materials and phase identification and for indexing. For structure 
solution and Rietveld refinement, the higher 2θ range was used. The powder X-ray 
diffraction data were collected in the form of a RAW file and converted to a UXD file 
for further analysis. The UXD file was then converted into .gsa and .xdd format files 
using Perl software for further analysis.  
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3.4 Single crystal X-ray diffraction data  
 
The crystal selected from the sample was reduced to a crystal size of 0.18x0.16x0.08 
mm
3
 using a crystal habit known as Cut Slab. The data were collected on a Bruker 
APEXII CCD diffractometer with a Bruker FR591 rotating anode (λMo-Kα = 0.71072 
Å) at 120 K in the range of 2.91°<2θ< 27.48° and with resolution between 7.00Å and 
0.77 Å.  
 
3.5 
1
H NMR spectra 
 
0.03g of sample material was dissolved in 2ml of d
6
 DMSO solvent as a reference in a 
5mm diameter quad probe. The data was recorded at 300MHz on a Bruker AC300 
spectrometer. 
 
 
3.6 Infra-red spectra 
 
IR data was collected on a Perkin Elmer 100 FTIR spectrometer and recorded in the 
range of 400 to 4000 cm
-1
. 
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4.  METHODOLOGY 
 
4.1 Indexing 
 
Indexing of powder X-ray diffraction data by selection of accurate unit cell 
parameters is the crucial step on which the whole structure determination procedure 
depends. XFIT
38
 is used to select peaks for input into the CRYSFIRE
39
 indexing 
software suite. Initially, the 20 most intense peaks are selected and saved in a text file 
for input into CRYSFIRE. Alternatively, the first (lowest 2θ) 20 observable peaks can 
be used. 
 
CRYSFIRE
39
 is used to index the powder X-ray diffraction pattern
40
 through the 
application of ten indexing algorithms. The results obtained from each indexing 
method are saved into a single summary file and listed in order of figure of merit 
F20
18
. The software CHEKCELL
41
 was then used to verify the fit between the peaks 
selected and peaks generated by different unit cells obtained through indexing. The 
space group is then assigned based on the conditions for systematic absences (hkl) in 
the unit cell, or in a triclinic case, based on density considerations. 
 
4.2 Le Bail pattern decomposition 
 
The Le Bail
42
 pattern decomposition method is a method used to refine the cell and 
other profile parameters without need for a structural model. GSAS
43
 is a software 
package than can be used to apply Le Bail pattern decomposition to powder X-ray 
diffraction data. Lattice parameters, pseudo voigt peak shape (a combination of 
Lorenzian and Gaussian) and zero point error are all refined during this process.  The 
fitness between the experimental and simulated powder X-ray diffraction patterns is 
measured in terms of Rwp (R-factor) and χ
2 44
. The peak intensities also act as variable 
parameters in Le Bail decomposition, whereas for a Rietveld refinement these are 
defined by atomic positions. The Le Bail method increases the accuracy of direct 
space structure solution methods to determine the crystal structure by ensuring that 
the lattice parameters and profile parameters give the best possible fit
44
. 
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4.3 Differential evolution (DE) structure solution 
 
The next stage of crystal structure determination is the structure solution process, in 
this project; based on the differential evolution method. Many evolutionary algorithms 
are inspired by natural evolutionary processes and principles of biological evolution
40
 
and are used to explore the global minima on the fitness landscape
40, 45, 46
. These 
evolutionary techniques are now used widely in chemistry, nanoscience and 
bioinformatics
47
. Traditional methods (direct and Patterson methods) used to find 
structure solutions for organic materials in powder form are often unsuccessful
19, 48
 
and hence the alternative direct space approach was developed. The traditional 
methods need extraction of intensities of individual diffraction maxima. Due to peak 
overlap problem in X-ray powder diffraction data, it is often difficult for traditional 
methods to extract unambiguous values of the intensities I (hkl) of the individual 
diffraction maxima. In direct space approach, in order to solve crystal structures from 
powder diffraction data, trial crystal structures are generated in direct space and the 
suitability of each trial structure is assessed by direct comparison between the powder 
diffraction pattern calculated for the trial structure and its experimental powder 
diffraction pattern
49
.  
 
Differential evolution (DE) is relatively new algorithm technique originally used to 
solve the Chebychev polynomial fitting problem
50
. The DE approach was given 
highest preference in the International contest in evolutionary computation which 
does not use any specialised problem information
51
. It has proved to be highly 
efficient in a range of chemical contexts, including X-ray scattering
52, 53
, protein 
crystallography
54
, molecular docking
55
, crystal epitaxy
56
, disordered crystal 
structures
55
, optimization of clusters
57
 and direct space crystal structure solution of 
crystalline materials from powder diffraction data
45
. 
 
The differential evolution program used in the current project was implemented in the 
POSSUM
58
 program suite. This program suite creates a control file which includes 
the details of the structural model(s), unit cell parameters and optimisation 
information used to direct the search and boundaries for the population hypersurface 
for the DE. In cases where specific crystallographic site symmetry is needed these 
values can be further constrained, enhancing the efficiency of the optimisation process 
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(see figure 4.2). The structural models are built on the basis that a crystal structure is 
the repetition of three dimensional models within the unit cell. The position and 
orientation of the three dimensional structural models are represented by various 
variables, e.g., the position (x, y, z) and orientation (θ, υ, ψ) and torsion angles to 
describe the molecular conformation (τ1, τ2,… τN). These variables are the allowed to 
vary between 0 and 1 for the position and the angles used to describe the molecular 
orientations will vary between 0
°
 and 360
°59
.  
 
In DE, the initial population Np is generated across the hypersurface, the size of which 
is directly proportional to the initial value given for Np. The fitness of each initial trial 
structure is assessed by comparing the calculated powder diffraction pattern to the 
experimental powder diffraction pattern. This is expressed in terms of the R-factor 
(Rwp).  
 
In a DE population, each offspring is produced from its parent and three random trial 
structures (see equation 3.1). The resulting child structure is the summation of the 
parent and difference between the parent and a random structure controlled by 
recombination (k) and the difference between two random structures controlled by 
mutation (F) as shown in the equation below. The parameters K and F can be varied 
between 0 and 1. With an increase in the value of K, the distance between the parent 
and the child structure will increase. The F value helps to maintain diversity in the 
population by including information from other individuals. The DE then uses the 
parameter boundary conditions to reset a child structure when a new offspring 
exceeds the boundaries of the fitness hypersurface.  
 
Child = Parent + K (Random1 - Parent) + F (Random2 - Random3)  
 
K  =  Recombination 
F = Mutation 
Child = Child structure 
Parent  = Parent structure 
Random1, Random2, Random3 = Random structures 
(3.1) 
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Figure 4.1: An example of an evolutionary progress plot for a DE calculation. 
 
In the early stages of a search, the trial structures are dispersed widely across the 
fitness hypersurface. And hence the difference between the R-factors of the first few 
generations are expected to be large (see figure 4.1). As the search progresses, the 
population converges and the R-factor difference between the best member and the 
other members of the population in each generation decreases
60
. 
 
Figure 4.2: An example of a 2D hypersurface clearly showing the global minimum 
which represents the best structure solution
1
. A local minimum is also shown. 
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4.4 Rietveld refinement 
 
The structure solution obtained from differential evolution is an approximate 
representation of crystal structure but should be close enough to the true structure to 
complete a quality crystal structure using Rietveld refinement. If all the atomic 
positions are within 1Å of the final refined structure, then the Rietveld refinement is 
usually successful
18
. Rietveld refinement in this work was performed using the GSAS 
& EXPGUI program package
43, 61
. During the refinement of structures, all bond 
lengths and angles are subjected to different restraints depending on the nature of the 
structures; the C-C bond lengths were restrained at 0.005Å and the C-H bonds 
restrained to 0.001Å. It is important to apply standard geometrical restraints in order 
to prevent excessive movement in atomic positions especially if an approximate 
structure solution has been obtained. Appropriate restraints are often imposed for 
successful refinement
60
. 
 
Rietveld refinement is based on the fitness between the experimental and calculated 
diffraction patterns measured in terms of R-factor (Rwp). By considering every point 
in the powder diffraction pattern as an individual intensity, the optimal fit between the 
calculated and experimental powder diffraction is obtained by applying least square 
minimisation methods
19
. 
 
4.5 Single crystal X-ray diffraction 
 
The data collection was driven by COLLECT
62 
and processed by DENZO
63
.
 
An 
absorption correction was applied using SADABS
64
. The structures were solved in 
SHELXS-97
65
 and were refined by a full-matrix least-squares procedure on F
2
 in 
SHELXL-97. All non-hydrogen atoms were refined with anisotropic displacement 
parameters. All hydrogen atoms were added at calculated positions and refined by use 
of a riding model with isotropic displacement parameters based on the equivalent 
isotropic displacement parameter (Ueq) of the parent atom. Figures were produced 
using ORTEP3 for Windows
66, 67
 while structural analysis was carried using 
PLATON
68
. 
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5.  RESULTS 
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5.  RESULTS 
 
A range of α,ω-di-carboxylic acids (HOOC-(CH2)n-COOH, where n= 0,1,2,4,5,6,7) 
have been investigated as potential former molecules to form co-crystals with 
nicotinamide (see figure 2.1(a)) and isonicotinamide (see figure 2.1(b)) using different 
solvents, different stoichiometric ratios and different methods of synthesis. The 
change in properties of these co-crystals is related to the sequential increase in the 
number of methylene groups in the di-carboxylic acid. The formation of new co-
crystals was confirmed using powder X-ray diffraction and solid state infrared 
spectroscopy. The stoichiometric ratios of the former molecules within the crystalline 
products were confirmed using solution nuclear magnetic resonance spectroscopy (
1
H
 
NMR). Infrared spectroscopy (IR) was also used to investigate the presence of 
intermolecular bonds in these materials. The melting points of all new crystal 
materials were determined and found to lie between the melting points of the starting 
materials. 
 
Indexing of the unit cells and Le bail pattern decomposition from powder X-ray 
diffraction were attempted for most of the new materials obtained. In addition, the 
crystal structures of two of the new co-crystal materials were determined. The crystal 
structure of the adipic acid : nicotinamide co-crystal was determined using single 
crystal X-ray diffraction data, whereas the crystal structure of the azelaic acid : 
nicotinamide co-crystal was determined from powder X-ray diffraction data.  
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5.1 Oxalic acid and nicotinamide 
 
Oxalic acid (see figure 2.2 (a)) was crystallised with nicotinamide using a range of 
different solvents and synthetic methods in different starting molar ratios. The solid 
products were formed immediately after the solutions containing the individual 
components were mixed. The appearance of new materials obtained using different 
synthesising methods, solvents and stoichiometric ratios for nicotinamide and oxalic 
acid in this series of experiments are all white crystalline solids. 
 
Crystallisation of oxalic acid with nicotinamide was done using different solvents 
(methanol and ethanol) in 1:1, 1:2 and 2:1 starting molar ratios. Solution 
crystallisation and solvent drop grinding (SDG) methods were both employed for the 
preparation of these new materials. Similar X-ray diffraction patterns were obtained 
for materials prepared using methanol and ethanol with 1:1 and 2:1 molar ratios 
illustrating formation of the same product (see figure 5.1.1). The X-ray powder 
diffraction patterns for the materials obtained from both 1:1 and 2:1 molar ratios are 
different compared to that 1:2. The product obtained from 1:2 also shows traces of 
peaks from the product with 1:1 ratio (or 2:1). It can be concluded from this data that 
it is a mixture of different new materials. Different synthetic approaches and molar 
ratios were used, but none of them were successful in the synthesis of this new 
material (from 1:2) in pure form. The same new materials (from 1:1 and 1:2) are 
formed reproducibly from both solution crystallisation (using both methanol and 
ethanol) and solvent drop grinding methods although in the latter case, starting 
materials were also present (see appendix A). 
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Figure 5.1.1: X-ray powder diffraction patterns of nicotinamide and oxalic acid and 
products of crystallisation using methanol. 
 
From the NMR spectra and consideration of the ratio of integral values of the peak 
intensities for protons in different environments in nicotinamide and oxalic acid, it is 
evident that the new material obtained by crystallisation of the starting materials in the 
1:1 and 2:1 molar ratios has the molecular formers crystallised in a 1:1 stoichiometric 
ratio (see figure 5.1.2). The other new material obtained (as a mixture) using starting 
materials in 1:2 stoichiometric ratio (see figure 5.1.3) indicates the presence of a 1:2 
oxalic acid : nicotinamide ratio in the adduct. The ratio between the molecular 
components in the new materials is interpreted by comparing the integral values of 
individual peak intensities for the H atoms in the coformers. In the spectrum shown 
below (see figure 5.1.2), the B1 peak is due to the two hydrogen atoms in the oxalic 
acid and the A1 peak is due to the single H atom in the ortho position. The integral 
value for A1 peak is approximately half that of B1. This implies that the molecular 
components are in a 1:1 ratio. In the next spectrum (see figure 5.1.3), the integral 
values of both A1 and B1 peaks are approximately equal, hence representing two 
hydrogen atoms each. This can only be the case if for each oxalic acid molecule there 
are two nicotinamide molecules and hence the adduct has a 1:2 acid : amide ratio. 
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Figure 5.1.2: 
1
H NMR of oxalic acid and nicotinamide adduct (from 1:1 starting 
ratio) using DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6): δ = 13.18(s, 2H), 
9.04(dd, 1H), 8.69(dd, 1H), 8.22(dt, 1H), 8.18(s, 1H), 7.62(s, 1H), 7.51(ddd, 1H).  
 
 
 
Figure 5.1.3: 
1
H NMR for the product of oxalic acid and nicotinamide adduct (from 
1:2 starting ratio) using DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6): δ = 
11.95(s, 2H), 9.05(dd, 2H), 8.70(dd, 2H), 8.19(dt, 2H), 8.17(s, 2H), 7.63(s, 2H), 
7.52(ddd, 2H).  
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Solid state FTIR spectroscopy can be used to investigate whether the product formed 
is a co-crystal or a salt. The data from the product obtained from the crystallisation is 
compared to that from a mixture of the starting materials. The oxalic acid in the 
starting material is characterised with very broad peaks obtained for  O-H stretching 
frequency with intense absorptions at 3470cm
-1
 and 3367cm
-1
. The peaks at 3171cm
-1
 
for the product show a downshift that may imply involvement in stronger 
intermolecular hydrogen-bonding.  The  peaks for  C=O stretching vibrations at 
1683cm
-1
 appear for  both the starting mixture and product.  The  peaks at 3331cm
-1
 
would belong to amide N-H stretching vibrations. The peaks at 3063cm
-1
would 
belong to aromatic C-H stretchings. Symmetric out-of-plane aromatic C-H  bending 
of the aromatic ring is at 710cm
-1
 and  peaks for  out of plane ring bending vibrations 
appear around 669cm
-1
. In R. F. Evans and W. Kyaston
69
, they showed that, if H is 
transferred from the acid to N within the hydrogen-bonding between the acid and 
pyridine ring, very broad peaks would appear around 2500±100cm
-1
 and for 
individual N
+
-H bonds, peaks would appear at 3250±50cm
-1
. None of these 
characteristics are observed so it is not conclusive whether or not the product is a co-
crystal or salt as the two spectra do not match either as might be expected if a 
cocrystal was formed (see figure 5.1.4). 
 
Figure 5.1.4: FTIR spectra for the product of oxalic acid and nicotinamide 
crystallisation (1:1). 
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Possible cell parameters were obtained for the 1:1 co-crystal by the indexing on the 
basis of the twenty most intense peaks in the powder diffraction pattern using the 
CRYSFIRE software suite. The possible cell parameters are chosen for Le bail pattern 
decomposition on the basis of stoichiometric ratio between the molecules obtained 
from NMR along with cell volume calculations and figure of merit (see Table 5.1.1). 
The space group was chosen on the basis of conditions for systematic absences in 
reflections for a unit cell with respective space group (see table 1). The accuracy of 
unit cell parameters and correct space group would be confirmed through Le bail 
pattern decomposition method (see figures 5.1.5).  The unit cell refinement is also 
done simultaneously during the pattern decomposition process. The best fit between 
the experimental data (red) and simulated pattern (green) is quantified in terms of R-
factor value (wRp) and χ2. The lowest R-factor and χ2 values obtained are 0.0956 and 
0.3241 respectively. 
 
 
Table 5.1.1 
 
Indexed and refined cell parameters obtained for the product of oxalic acid and 
nicotinamide 
 
 
 
Figure of 
Merit / Rwp / 
χ2 
a(Å) b(Å) c(Å) α(o) β(o) γ(o) 
Cell volume 
(Å3) 
Space group 
PXRD 
indexing 
14.77 12.848 6.349 11.244 90.00 104.61 90.00 887.684 P21/c 
PXRD Le bail 
fit 
Rwp= 0.1129  
χ2=18.61 
12.822 6.347 11.213 90.00 104.75 90.00 882.692 P21/c 
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Figure 5.1.5: The Le bail profile fitting for the product of oxalic acid and 
nicotinamide crystallisation (1:1). 
 
 
No further structural characterisation was carried out on this product. 
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5.2 Malonic acid and nicotinamide 
 
Malonic acid (see figure 2.2(b)) was crystallised together with nicotinamide using 
different synthetic methods and solvents. All new materials were synthesized as white 
solid clusters. Crystallisation of malonic acid with nicotinamide was carried out in 
1:1, 1:2 and 2:1 starting molar ratios, using different solvents (methanol and ethanol) 
both in solvent-mediated crystallisation and solvent drop grinding (see appendix B). 
The X-ray powder diffraction patterns for materials obtained from methanol and 
ethanol in 1:1 and 2:1 starting molar ratios shows the formation of the same product 
(see figure 5.2.1). For each stoichiometric ratio the new materials obtained using 
different solvents and synthesising methods are the same. However, it is evident that 
the new materials obtained from 1:1 and 1:2 stoichiometric ratios are different and 
differ from the starting materials (see figure 5.2.1).  
 
5 15 25 35 45 55
2-Theta
In
te
n
s
it
y
Malonic acid and nicotinamide adduct (2:1)
Malonic acid and nicotinamide adduct (1:2)
Malonic acid and nicotinamide adduct (1:1)
Malonic acid
Nicotinamide
Figure 5.2.1: X-ray powder diffraction patterns of nicotinamide and malonic acid and 
products of crystallisation using methanol.  
 
From the integral values of different peak intensities for protons in different 
environments on malonic acid and nicotinamide obtained from NMR spectra, it is 
evident that the new materials obtained from starting molar ratios of 1:1 and 1:2 are 
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obtained with approximate 1:1 and 1:2 stoichiometric ratios (see figures 5.2.2 and 
5.2.3). 
 
Figure 5.2.2: 
1
H NMR of malonic acid and nicotinamide (1:1) crystallisation using 
DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6): δ= 12.51(s, 2H), 9.03(dd, 1H), 
8.70(dd, 1H), 8.20(dt, 1H), 8.17(s, 1H), 7.61(s, 1H), 7.51(ddd, 1H), 3.26(s, 2H). 
 
Figure 5.2.3: 
1
H NMR of malonic acid and nicotinamide (1:2) crystallisation using 
DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6): δ= 12.67(s, 2H), 9.03(dd, 2H), 
8.68(dd, 2H), 8.21(dt, 2H), 8.19(s, 2H), 7.61(s, 2H), 7.48(ddd, 2H), 3.25(s, 2H). 
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The solid state FTIR data for the products (1:1 and 1:2) obtained from the 
crystallisation are compared to that from a mixture of the starting materials. For a 
discussion of characteristic peaks of nicotinamide, please see section 5.1. The C=O 
stretching frequency bands of the amide group can be observed between 1684 cm
-1 
and 1599 cm
-1
. The peaks at 3368cm
-1
 (1:1) and 3374cm
-1
 (1:2) indicate N-H 
stretching frequency bands for the amide group in the product formed. The absence of 
characteristic high tone at 3000 cm
-1
 (O-H bond stretching frequency of a carboxylic 
acid) indicates the involvement of the carboxylic acid groups in intermolecular 
bonding. The peaks at 3173cm
-1
 (1:1) and 3171cm
-1
 (1:2) in both spectra may imply 
the involvement of O-H bonds in stronger hydrogen bonding. Interpretation of the IR 
spectra for different molecular fragments supports the presence of neutral 
intermolecular bonds. There are similarities between the spectra obtained for the 
product and starting materials, albeit the shift of some bands mentioned previously. 
This implies, although not conclusively, that there has been no proton transfer from 
the hydroxyl group to the heterocyclic nitrogen (see figures 5.2.4 and 5.2.5) and hence 
that in both cases a co-crystal rather than a salt has been formed. 
 
 
Figure 5.2.4: FTIR spectra of malonic acid and nicotinamide and the product of 
crystallisation (1:1). 
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Figure 5.2.5: FTIR spectra of malonic acid and nicotinamide and products of 
crystallisation (1:2). 
 
The X-ray powder diffraction pattern of the crystallised product (malonic acid: 
nicotinamide 1:1) was indexed using CRYSFIRE, on the basis of the twenty most 
intense peaks selected using XFIT. Possible cell parameters were assessed on the 
basis of stoichiometric ratios between the former molecules obtained from NMR. The 
most highly ranked unit cell (see table 5.2.1 and appendix C) indexed all twenty peaks 
successfully and was conducive with density considerations for a 1:1 ratio. These cell 
parameters were refined using Le bail pattern decomposition.  
 
Table 5.2.1 
 
Indexed cell parameters of malonic acid and nicotinamide: 
 
 
Figure of 
Merit / Rwp / 
χ2 
a(Å) b(Å) c(Å) α(o) β(o) γ(o) 
Cell volume 
(Å3) 
Space group 
PXRD 
indexing 
23 10.444 10.277 5.121 96.09 103.88 67.38 492 P1 
PXRD Le bail 
fit 
Rwp= 0.1085 
χ2=0.9889 
10.431 10.234 5.102 96.12 103.87 67.32 492 P1 
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Figure 5.2.6: The Le bail profile fitting for nicotinamide and malonic acid 
crystallisation (1:1). 
 
No further structural characterisation was carried out on this product. 
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5.3 Succinic acid and nicotinamide 
 
Succinic acid (see figure 2.2(c)) was crystallised with nicotinamide in 1:1 starting 
stoichiometric ratio using different synthetic methods and solvents. All new materials 
were synthesized as white solid clusters. Crystallisation was performed using solvent 
mediated crystallisation and SDG methods in methanol and ethanol (see figure 5.3.1). 
The X-ray diffraction patterns for materials obtained from different synthesising 
methods and solvents shows the formation of the same new product (see appendix D), 
although there are clearly traces of succinic acid in the product from SDG. 
 
 
Fig 5.3.1: Powder X-ray diffraction patterns of succinic acid and nicotinamide and 
products of crystallisation from methanol. 
 
From the integral values of different peak intensities for protons in different 
environments on succinic acid and nicotinamide obtained from NMR spectra, it is 
evident that the stoichiometric ratios in the product formed is 1:1 (see figure 5.3.2).  
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Figure 5.3.2: 
1
H NMR of succinic acid and nicotinamide (1:1) crystallisation using 
DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6): δ= 12.15(s, 2H), 9.02(dd, 1H), 
8.68(dd, 1H), 8.19(dt, 1H), 8.16(s, 1H), 7.59(s, 1H), 7.48(ddd, 1H), 2.42(s, 4H). 
 
The solid state FTIR data (figure 5.3.3) for the product obtained from crystallisation 
was compared to that obtained from the starting materials. The spectra for the new 
material succinic acid : nicotinamide (1:1) have few similar peaks to that in sections 
5.1 and 5.2 showing characteristic IR bands of different molecular fragments in 
succinic acid and nicotinamide. The similarity between the spectra obtained for the 
product and the starting materials infers that the product could be a co-crystal. There 
may be indication of a two broad peaks at ~2474 cm
-1 
and 1912 cm
-1
. This implies, 
although not conclusively, there has been no proton transfer from the hydroxyl group 
to the heterocyclic nitrogen and hence a co-crystal rather than a salt has been formed.  
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Figure 5.3.3: FTIR spectra of succinic acid and nicotinamide and products of 
crystallisation (1:1). 
 
This material has not been indexed due to constraints of project time. 
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5.4 Adipic acid and nicotinamide 
 
Adipic acid (see figure 2.2(d)) was crystallised with nicotinamide using different 
synthetic methods and solvents. All new materials were obtained as white solid 
clusters. Crystallisation of adipic acid and nicotinamide was attempted in 1:1, 1:2 and 
2:1 starting molar ratios and performed with methanol and ethanol both in solvent-
mediated crystallisation and solvent drop grinding (see appendix E). Similar X-ray 
powder diffraction patterns were obtained for different solvents and different starting 
molar ratios (e.g: adipic acid and nicotinamide 2:1), showing the formation of the 
same product (see figure 5.4.1). The new materials obtained from some different 
starting molar ratios, solvents and preparation methods were found to contain a 
mixture of product and adipic acid (starting material) (see appendix E).  
 
 
 Figure 5.4.1: X-ray powder diffraction patterns of nicotinamide and adipic acid and 
products of crystallisation using methanol. 
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From the integral values of different peak intensities for protons in different 
environments on adipic acid and nicotinamide obtained from the NMR spectra, it is 
evident that the new material obtained from the 1:2 and 1:1 crystallisations has the 
molecular formers crystallised in 1:2 adipic acid : nicotinamide stoichiometric ratio 
(see figure 5.4.2). 
 
 
Figure 5.4.2: 
1
H NMR of nicotinamide and adipic acid adduct using DMSO as 
solvent. 
1
H NMR 300MHz (DMSO-d6): δ = 12.03(s, 2H), 9.02(dd, 2H), 8.68(dd, 2H), 
8.19(dt, 2H), 7.62(s, 2H), 7.50(ddd, 2H), 2.50(m, 4H), 2.30(m, 4H). 
 
The solid state IR data for the new material obtained from crystallisation and the 
starting materials are compared. The spectra for the new material and the former 
products are similar. See sections 5.1 and 5.2 for the characteristic IR peaks of 
different molecular fragments in nicotinamide and adipic acid molecules. The 
similarity between the spectra obtained for the product and the mixture of starting 
materials (except for the shift of bands) supports the absence of salt formation and 
implies co-crystal formation (see figure 5.4.3) although not conclusively. 
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Figure 5.4.3: FTIR spectra of adipic acid and nicotinamide and product of 
crystallisation (1:2). 
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5.4.1 Determination of crystal structure from single crystal X-ray diffraction 
data (SXRD) 
 
The crystal structure of the adipic acid : nicotinamide (1:2) co-crystal was 
successfully solved from single crystal X-ray diffraction data (see appendix F, G, H 
and see table 5.4.1). The unit cell parameters obtained from the powder X-ray 
diffraction data and single X-ray diffraction data are similar (see table 5.4.1) with the 
only difference being the expected contraction with temperature. The stoichiometric 
ratio of the adipic acid and nicotinamide established from NMR is confirmed as 1:2 
by the single-crystal structure. Figure 5.4.1.1 shows the atom labelling used in this 
structure and clearly shows the adduct in neutral co-crystalline form with one half of 
the adipic acid molecule generating the other half through inversion symmetry.  
 
The supramolecular structure of adipic acid : nicotinamide (1:2) is determined through 
four intermolecular hydrogen bonds; one soft C-H
…
O=C hydrogen bond and three 
strong hydrogen bonds, two N-H
…
O=C type and one O-H
…
N(heterocyclic) 
interaction (see table 5.4.2), such that all strong hydrogen-bond donors and acceptors 
are used in the intermolecular network(see figure 5.4.1.2 (I)). 
 
The nicotinamide and adipic acid molecules are linked by a O-H…N(heterocyclic) 
hard hydrogen bond confirming that the components remain in their neutral form in 
cocrystal (rather than salt) formation.  The carboxyl oxygen O4 at (x, y, z) acts as a 
hydrogen bond donor, via H4, to the heterocyclic N1 of the nicotinamide at (x, y, z), 
while this packing is reinforced by C6 in nicotinamide at (x, y, z) acting as a 
hydrogen-bond donor through H6 to the other carboxyl oxygen O3 also at (x, y, z).  
Propagation of these two hydrogen bonds through inversion symmetry within the 
adipic acid molecule generates the 1:2 adipic acid : nicotinamide building block in 
which the adipic acid molecule is capped at both ends by nicotinamide molecules at 
(x, y, z) and (-x, 2-y, 1-z).  
 
Each nicotinamide molecule is connected to another through complementary N-H…O 
hydrogen bonds in which N2 at (x, y, z) acts as a donor via H2A to O1 at (-x, 2-y, 1-z) 
and O1 at (x, y, z) acts as an acceptor from N2 via H2A at (-x, 2-y, 1-z).  The resulting 
amide-amide dimer (an R
2
2(8) ring) links the 1:2 adipic acid : nicotinamide building 
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blocks together into an infinite zig-zag chain running in the [201] direction (see figure 
5.4.1.2 (II)). 
 
These chains are then linked together into a hydrogen-bonded sheet through the 
second N-H…O=C interaction forming a C(4) chain running parallel to the a-axis.  
The amide N2 at (x, y, z) forms this hydrogen bond through H2B to O1 at (1+x, y, z) 
while O1 at (x, y, z) also acts as an acceptor of H2B at (-1+x, y, z).  Propagation of this 
hydrogen bond around the inversion centre at (0, 0.5, 0) results in the formation of 
infinite hydrogen-bonded ladders, running in the [100] direction, containing 
alternating R
2
2(8) and R
2
4(8) rings (see figure (I)).  
 
 
 
 
 
 
Figure 5.4.1.1: ORTEP diagram of the adipic acid : nicotinamide (1:2) co-crystal 
showing the strong hydrogen bond interaction between the two former molecules. 
Thermal ellipsoids are drawn at the 50% probability level.  
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Table 5.4.1 
 
Summary of crystal data for adipic acid and nicotinamide co-crystal obtained from 
SXRD. 
Empirical formula 2(C6 H6 N2 O), C6 H10 O4 
Fw 390.40 
T [K] 120(2) 
λ [Å] 0.71073 
Crystal system Triclinic 
Space group P -1 
a[Å] 5.0261(2) 
b[Å] 5.4280(3) 
c [Å] 16.8981(10) 
α[°] 98.147(2) 
β[°] 91.072(3) 
γ[°] 90.588(3) 
V[Å
3
] 456.24(4) 
Z 1 
Dm[mg/m
3
] 1.421 
Absorption coefficient 0.108 mm
-1
 
F(000) 206 
Crystal size [mm
3
] 0.18 x 0.16 x 0.08 
2θ range [°] 3.65 to 27.48 
Index ranges -6<=h<=6, -7<=k<=7, -21<=l<=21 
Reflections observed 7324 
Independent reflections 2058[R(int) = 0.0331] 
Completeness to theta = 27.48˚ 98.5% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9914 and 0.9808 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 2058 / 0 / 128 
Goodness of fit on F
2
 1.115 
R [I > 2σ(I)] R1 = 0.0468, wR2 = 0.1294 
R indices (all data) R1 = 0.0509, wR2 = 0.1327 
Largest diff. peak and hole 0.340 and -0.284 e.Å-3 
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Table 5.4.2 
 
Intermolecular hydrogen bond parameters [Å, °] in the adipic acid : nicotinamide 
(1:2) co-crystal. 
 
_____________________________________________________________________ 
D-H
...
A   d(D-H) d(H
...
A) d(D
...
A) <(DHA) 
_____________________________________________________________________ 
 N(2)-H(2A)
...
O(1)(ii)  0.88  2.06  2.9260(16) 167.9 
 N(2)-H(2B)
...
O(1) (iii) 0.88  2.14  2.8851(17) 141.4 
 O(4)-H(4A)
...
N(1) (i)  0.84  1.85  2.6865(17) 174.2 
 C(6)-H(6)
....
O(3) (i)  0.95  2.70  3.3686(18) 127.9 
_____________________________________________________________________ 
 
Symmetry transformations used to generate equivalent atoms:  
(i)-x,-y+2,-z+1   (ii) -x+2,-y+2,-z    (iii) x+1,y,z  
 
 
 
Figure 5.4.1.2 (I): A view of the crystal structure of adipic acid : nicotinamide (1:2) 
down [010] showing the intermolecular interactions between the molecules within a 
sheet.  
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Figure 5.4.1.2 (II): A view of the crystal structure showing a projection down [100] 
illustrating the padding of sheets in adipic acid : nicotinamide (1:2) and zigzag 
sheets. 
 
5.4.2 Determination of crystal structure from powder X-ray diffraction data 
(PXRD) 
 
Once the crystallisation of a new adipic acid : nicotinamide (1:2) co-crystal was 
confirmed (using PXRD, NMR and IR), full crystal structure analysis was attempted 
from X-ray powder diffraction data. Possible unit cell parameters were obtained by 
indexing the 20 most intense peaks in the powder X-ray diffraction pattern selected 
using XFIT
38
 software. CRYSFIRE
39
 was then used to run different indexing programs 
and used to index the selected peaks (see appendix I). Possible unit cell parameters 
were chosen for further analysis on the basis of density considerations of the 
stoichiometric ratio of the co-crystal (obtained from NMR) along with cell volume 
and consideration of the figure of merit (see Table 5.4.3). Both space groups P1 and 
P-1 are possible for the structure: P1 would require both nicotinamide molecules and 
the adipic acid molecules to occupy general positions whereas in P-1 the second 
nicotinamide molecule would be generated by crystallographic symmetry and the 
adipic acid molecule would sit on the inversion centre. The accuracy of this chosen 
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unit cell can be confirmed through Le bail pattern decomposition.  The refined unit 
cell and the fit between the calculated and experimental powder X-ray diffraction 
patterns by Le bail pattern decomposition are shown in table 5.4.3 and figure 5.4.2.1. 
The best fit between the experimental data (red) and simulated pattern (green) is 
quantified in terms of R-factor value Rwp and χ
2
. The Le bail fit was then used as a 
starting point for the structure solution process from X-ray powder diffraction data 
(see figure 5.4.2.2).  
 
Table 5.4.3  
Cell parameters and space group from powder diffraction and single crystal data. 
 
Figure of 
Merit 
a(Å) b(Å) c(Å) α(o) β(o) γ(o) 
Cell 
volume 
(Å3) 
Space 
group 
PXRD 
indexing 
57.61 5.505 17.128 5.039 90.16 90.67 96.75 471.88 P-1  
PXRD Le bail 
fit 
Rwp= 0.097 
χ2=0.92 
5.493 17.103 5.034 90.93 96.78 89.71 469.27 P-1 
Single crystal 
structure 
(120K) 
R1 = 0.0468, 
wR2 = 
0.1294 
5.428
(3) 
16.898 
(10) 
5.026 (2) 
91.07 
(3) 
90.58 
(3) 
98.14 
(2) 
456.24 
(4) 
P-1 
 
 
 
Figure 5.4.2.1: The Le bail profile fit for the adipic acid : nicotinamide (1:2) co-
crystal. 
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Structure solution was carried out using the DE technique (implemented in the 
program POSSUM
58
). The adipic acid molecule was fixed at the inversion centre (0, 
0, 0) such that one half of the molecule generated the other. The molecule was 
allowed to rotate around this pivot with torsional variation as shown (figure 5.4.2.2). 
The nicotinamide was allowed to translate and rotate with torsional flexibility as 
shown in (figure 5.4.2.2). In total, the structure solution had 11 degrees                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
of freedom. The H atoms in amide and carbonyl functional groups are weak scatters 
and would increase the number of degrees of freedom needed in the global minimum 
search process, hence, these were not included in the structure solution. The DE was 
run using a population size of 35 and control parameters K = 0.99 and F = 0.3. The 
best solution obtained from 5 epochs gave a structure with Rwp = 0.1706. The 
evolutionary progress plot for this calculation is shown in figure 5.4.2.2. 
 
Figure 5.4.2.2:  Molecular structures of nicotinamide and one half of adipic acid 
molecules showing the torsion angles used in the direct-space structure solution 
calculation. 
 
Comparison between the structure solution obtained from PXRD and crystal structure 
obtained from SXRD shows the N and O atoms in the amide in the functional group 
of nicotinamide are swaped (see figures 5.4.1.2(I) and 5.4.2.3). This is not surprising 
as N and O have similar electron density and may not always be discriminated during 
the application of direct space methods from PXRD. Rietveld refinement was not 
carried out for this structure as the crystal structure was already rationalised from 
PXRD. 
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Figure 5.4.2.3: Evolutionary progress plot for the best DE calculations for the 
product of adipic acid : nicotinamide (1:2). 
 
 
 
Figure 5.4.2.4: A view of the crystal structure of adipic acid : nicotinamide (1:2) 
showing the different amide conformation obtained from the structure solution from 
PXRD.  
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5.5 Pimelic acid and nicotinamide 
 
Pimelic acid (see figure 2.2(e)) was crystallised independently with both nicotinamide 
and isonicotinamide. In the case of nicotinamide the crystallisation was carried out 
using methanol in a 1:1 starting molar ratio using traditional solvent crystallisation. 
The different X-ray powder diffraction patterns for the product formed and the 
starting materials illustrate the formation of a new material (see figure 5.5.1). This 
new product formed as a white crystalline solid. 
 
Figure 5.5.1:  X-ray powder diffraction patterns for pimelic acid and nicotinamide 
and the product of crystallisation using methanol. 
 
From the integral values of peak intensities for protons in different environments on 
pimelic acid and nicotinamide obtained from the NMR spectra, it is evident that the 
new material obtained from a starting molar ratio of  1:1  has a 1:1 stoichiometric 
ratio (see figure 5.5.2). 
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Figure 5.5.2: 
1
H NMR of pimelic acid and nicotinamide crystallisation (1:1) using 
DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6): δ = 12.60(s, 2H), 9.03(dd, 1H), 
8.68(dd, 1H), 8.19(dt, 1H), 7.61(s, 1H), 7.49(ddd, 1H), 2.18(m, 4H), 1.48(m, 4H), 
1.25(m, 2H). 
 
The IR data for the new (1:1) material obtained from crystallisation and the starting 
materials are compared in figure 5.5.3. As in previous sections, there are characteristic 
IR peaks of different molecular fragments in nicotinamide and pimelic acid. The 
absence of a characteristic high tone at 3000 cm
-1
 for the O-H bond stretching of 
carboxylic acid shows the involvement of the carboxylic acid group in intermolecular 
bonds. Again there are similarities between the spectra obtained for the product and 
the mixture of starting materials apart from the shift of bands. There is an indication 
of broad peak ~2500cm
-1
 that may imply salt formation but this is not conclusive. 
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Figure 5.5.3: The FTIR spectra of pimelic acid and nicotinamide and the product of 
crystallisation. 
 
No attempt has been made to index the pimelic acid : nicotinamide (1:1) adduct due to 
constraints of the project time. 
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5.6  Pimelic and isonicotinamide 
 
Pimelic acid was crystallised with isonicotinamide using traditional solvent mediated 
crystallisation with methanol. This crystallisation was done in a 1:1 starting molar 
ratio and gave rise to white solid material. The X-ray powder diffraction pattern for 
the material formed was different in comparison to the starting materials showing 
formation of new adduct (see figure 5.6.1).  However, there may also be some pimelic 
acid in this sample. Indexing of the new material would address this observation. 
 
 
Figure 5.6.1: X-ray powder diffraction pattern for pimelic acid and isonicotinamide 
and products of crystallisation using methanol. 
 
From the integral values of different peak intensities for protons in different 
environments on pimelic acid and isonicotinamide obtained from the NMR spectra, it 
is evident that the new material obtained from the starting stoichiometric ratios of 1:1 
also has a 1:1 stoichiometric ratio (see figure 5.6.2). 
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Figure 5.6.2: 
1
H NMR of pimelic acid and isonicotinamide (1:1) crystallisation using 
DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6): δ = 12.52(s, 2H), 8.69(dd, 2H), 
8.26(s, 1H), 7.75(dd, 2H), 7.73(s, 1H), 2.38(m, 4H), 1.43(m, 4H), 1.26(m, 2H).  
 
The solid state IR data for product obtained from crystallisation and mixture of 
starting materials are compared. As the structures for nicotinamide and 
isonicotinamide are similar, we would expect the IR spectra for these two compounds 
to look similar. The C=O stretching frequency bands of amide group can be observed 
between 1692 and 1548 cm
-1
. The N-H stretching frequency bands of the amide group 
at 3354 cm
-1
 show the formation of intermolecular bonding and characteristic bands at 
671 cm
-1
 and 721 cm
-1
 indicate the monosubstituted aromatic ring. The absence of a 
characteristic high tone at 3000 cm
-1
 for O-H bond stretching frequency of the 
carboxylic acid shows the involvement of the carboxylic acid in intermolecular 
bonding. Many features of these spectra are similar for the product and the starting 
materials. However, as in the case of pimelic acid : nicotinamide (1:1) there are 
indications of a broad band at ~ 2500 raising the possibility that this adduct could be 
in salt rather than neutral form. From 5.5.3 and 5.6.3 it is likely that both pimelic acid 
: nicotinamide and pimelic acid : isonicotinamide  are in the same form. 
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Figure 5.6.3: FTIR spectra of pimelic acid and isonicotinamide and the product of 
crystallisation. 
 
No attempt has been made to index the pimelic acid : isonicotinamide (1:1) adduct 
due to constraints of the project time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RAJA SEKHAR VOGURI                                   RESULTS 
_____________________________________________________________________ 
 68 
5.7 Suberic acid and nicotinamide 
 
Suberic acid (see figure 2.2(f)) was crystallised with nicotinamide using different 
solvents with the components/starting molar ratios in different molar ratios. 
Crystallisation was carried out using methanol and ethanol and in 1:1, 1:2 and 2:1 
starting molar ratios. Solvent mediated crystallisation and solvent drop grinding 
methods were employed. All new materials obtained from crystallisation were white 
solids. For each starting stoichiometric ratio, the same new material was obtained 
from different solvents and synthesis methods. From the powder X-ray diffraction 
data, it is evident that two new materials were obtained from the 1:1 (2:1) and the 1:2 
stoichiometric ratios are different and differ from the starting materials (see figure 
5.7.1). 
 
 
Figure 5.7.1: X-ray powder diffraction pattern for suberic acid and nicotinamide and 
products of crystallisation from methanol. 
From the integral values of different peak intensities for protons in different 
environments on suberic acid and nicotinamide obtained from NMR spectra, it is 
evident that the new materials obtained by crystallisation of the starting materials in 
molar ratios of 1:1 and 1:2 are obtained with 1:1 and 1:2 stoichiometric adduct ratios 
(see figures 5.7.2 and 5.7.3).   
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Figure 5.7.2: 
1
H NMR of suberic acid and nicotinamide (1:1) adduct (from 1:1 
starting ratio) using DMSO as solvent.
 1
H NMR 300MHz (DMSO-d6):  δ = 11.97(s, 
2H), 9.02(dd, 1H), 8.68(dd, 1H), 8.19(dt, 1H), 8.16(s, 1H), 7.60(s, 1H), 7.47(ddd, 
1H), 2.18(m, 4H), 1.47(m, 4H), 1.25(m, 4H). 
 Figure 5.7.3: 
1
H NMR of suberic acid and nicotinamide (1:2) adduct (from 1:2 
starting ratio) using DMSO as solvent.
 1
H NMR 300MHz (DMSO-d6): δ= 11.99(s, 
2H), 9.04(dd, 2H), 8.69(dd, 2H), 8.20(dt, 2H), 7.62(s, 2H), 7.49(ddd,2H), 2.18(m,4H), 
1.47(m,4H), 1.25(m,4H). 
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The IR data for the product obtained from crystallisation (1:1) is compared to that 
from a mixture of starting materials (figure 5.7.4). The absence of characteristic high 
tones at 3000cm
-1
 for the O-H bond stretching frequency for a carboxylic acid shows 
the involvement of the carboxylic acid group in intermolecular bonding. For a 
discussion of the characteristic peaks of the starting materials, see sections 5.1 and 
5.2. There are similarities between the spectra obtained for the products and starting 
materials, but there are also indications of a potential broad band at ~2454cm
-1
 and 
hence the discrimination between neutral co-crystal and salt form is again not clear. 
 
 
Figure 5.7.4: FTIR spectra for suberic acid and nicotinamide and product of 
crystallisation (1:1). 
 
The IR data was not obtained for suberic acid : nicotinamde (1:2) adduct due to the 
time limitation and shortage of crystallised sample. No attempt has been made to 
index the suberic acid : nicotinamide (1:1 and 1:2) adducts due to constraints of the 
project time. 
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5.8 Suberic acid and isonicotinamide 
 
Suberic acid was crystallised using traditional solvent mediated synthesis with 
isonicotinamide in methanol using a starting 1:1 molar ratio. The new material was 
formed as a white solid. The X-ray powder diffraction pattern for the material formed 
was different in comparison to starting materials, showing the formation of a new 
material (see figure 5.8.1).  
 
2-Theta 
Figure 5.8.1: X-ray powder diffraction patterns of suberic acid and isonicotinamide 
and products of crystallisation using methanol. 
 
From the integral values of different peak intensities for protons in different 
environments on suberic acid and isonicotinamide obtained from NMR spectra, it is 
evident that this new material contains the starting components in a 1:1 stoichiometric 
ratio (see figure 5.8.2). 
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Figure 5.8.2: 
1
H NMR of suberic acid and isonicotinamide adduct (from 1:1starting 
ratio) using DMSO as solvent.
 1
H
 
NMR 300MH (DMSO-d6): δ = 12.01(s, 2H), 
8.70(dd, 2H), 8.25(s, 1H), 7.77(dd, 2H), 7.73(s, 1H), 2.17(m, 4H), 1.47(m, 4H), 
1.24(m, 4H). 
 
The IR data for the crystallisation product (1:1) is compared to that from a mixture of 
the starting materials (figure 5.8.3). For a discussion of characteristic IR peaks of the 
starting materials, please see sections 5.2 and 5.6. The absence of characteristic high 
tones at 3000cm
-1
 for O-H bond stretching frequency for a carboxylic acid shows the 
involvement of the carboxylic acid group in intermolecular bonding. There are also 
indications of a potential broad band at ~2496cm
-1
 and hence the discrimination 
between neutral co-crystal and salt form is again not clear.  
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Figure 5.8.3: FTIR spectra for suberic acid and isonicotinamide and product of 
crystallisation (1:1). 
 
No attempt has been made to index the Suberic acid : nicotinamide (1:1) adduct due to 
constraints of the project time. 
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5.9 Azelaic acid and nicotinamide 
 
Azelaic acid (see figure 2.2(g)) was crystallised individually with both nicotinamide 
and isonicotinamide. In the case of nicotinamide, the crystallisation was carried out 
using methanol in 1:1, 1:2 and 2:1 starting molar ratios and performed using methanol 
and ethanol (in 1:1 only) both in solvent-mediated crystallisation and SDG methods 
(see appendix I). The different X-ray powder diffraction patterns for the product 
formed and the starting materials illustrate the formation of a new material (see figure 
5.9.1). It is clear that other solvents also give the new product, but that in products 
from SDG mixtures of product and starting materials are obtained. The X-ray powder 
diffraction patterns obtained for all molar ratios, solvents and synthesizing methods 
are similar showing the formation of same product for different combinations. 
However, it is clear that in the 1:2 crystallisation, the new product is obtained in a 
mixture with some nicotinamide ; in the case of the 2:1 crystallisation there is azelaic 
acid also present. The presence of very little starting materials can be observed in the 
product obtained from 1:1 crystallisation 
 
 
Figure 5.9.1: X-ray powder diffraction patterns for nicotinamide and azelaic acid and 
products of crystallisation using methanol. 
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From the integral values of different peak intensities for protons in different 
environments on azelaic acid and nicotinamide in the NMR spectra of the product 
obtained from 1:1 crystallisation, it is evident that the new material has a 1:1 
stoichiometric ratio (see figure 5.9.2). 
 
Figure 5.9.2:  
1
H NMR for the product of nicotinamide and azelaic acid 
crystallisation using DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6):  δ = 11.97(s, 
2H), 9.03(dd, 1H), 8.68(dd, 1H), 8.19(dt, 1H), 7.60(s, 1H), 7.49(ddd, 1H), 2.18(m, 
4H), 1.47(m, 4H), 1.23(s, 6H).  
 
The solid state IR data for the product is compared to that from a mixture of the 
starting materials. For a discussion of the characteristic peaks of nicotinamide, please 
refer sections 5.1 and 5.2. Interpretation of the IR spectra for different molecular 
fragments supports the presence of neutral intermolecular bonds. The similarities 
between the spectra obtained for the product and starting materials apart from shift of 
bands implies, although not conclusively, that there has been no proton transfer from 
the hydroxyl group to the heterocyclic nitrogen and hence the product formed would 
be a co-crystal rather than a salt. However, there is also a potential evidence of the 
broad peak at ~2466 cm
-1
 (see figure 5.9.3)  
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Figure 5.9.3: FTIR spectra of azelaic acid and nicotinamide and product of 
crystallisation (1:1). 
 
 
 
 
 
 
 
 
 
 
 
5.9.1 Determination of unit cell parameters from X-ray powder diffraction data 
 
The X-ray powder diffraction data was indexed using CRYSFIRE
39
 on the basis of the 
20 most intense peaks. Peaks were selected from the experimental PXRD using 
XFIT
38
. Additional information from the NMR was used to estimate the number of 
structural units in the asymmetric unit cell and help to identify the most probable unit 
cell with density considerations (see appendix L and table 5.9.1.1). Consideration of 
systematic absences gave the space group Pna21, as the most probable. This unit cell 
was then used as a starting point for Le bail profile fitting as shown in figure 5.9.1.1. 
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Table 5.9.1.1 
 
Indexed and refined cell parameters obtained for the product of azelaic acid and 
nicotinamide: 
 
 
Figure of 
Merit 
a(Å) b(Å) c(Å) α(o) β(o) γ(o) 
Cell volume 
(Å3) 
Space 
group 
PXRD 
indexing 
20 8.796 36.345 5.211 90 90 90 1665.95 Pna21 
PXRD Le bail 
fit 
Rwp= 0.0916/ 
0.6565 
8.881 36.795 5.258 90 90 90 1718.55 Pna21 
 
 
 
Figure 5.9.1.1:  The Le Bail profile fitting for azelaic acid : nicotinamide (1:1) 
adduct. The greeen solid line shows calculated intensities  and points superimposed 
on it are observed intensities. The difference between the calculated and observed 
intesities is shown by pink line. Reflection positions are also shown. 
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5.9.2 Determination of Structure Solution using Differential Evolution (DE) 
 
The X-ray powder diffraction data used to run differential evolution calculations 
(using POSSUM
58
) for crystal solution was collected in the range 5°
 
< 2θ < 90°. The 
maximum number of epochs set for each run was 5 and population size was Np = 35. 
The rate of recombination (K) was set constant at 0.99 and a range of mutation rates 
(F) 0.2, 0.3, 0.4 and 0.5 used for structure solution. The structural models for solution 
comprised one molecule of azelaic acid and one nicotinamide excluding H atoms in 
amide and carboxylic acid functional groups.  
 
The molecules were allowed free orientation and translation in the unit cell with 
torsion angles as shown. The no. of degrees of freedom was 15. The results for the 
different DE control parameters are shown in figures 5.9.2.1-5.9.2.4. In the case of 
F=0.2, the calculation clearly shows premature convergence of all the calculations, 
F=0.3 performed the best. The global minimum (the structure solution with Rwp = 
0.146) has been found three times (other solutions with Rwp = 0.1419 and 0.1484). For 
F = 0.4, only one promising solutin was identified with an Rwp = 0.1535. In the case of 
F = 0.5, n o runs converged within the maximum generations allowed. The best 
structure solution (from F = 0.3, Rwp = 0.1416) was then used as a starting point for 
Rietveld refinement.  
 
 
 
 
Figure 5.9.2.1:    Evolutionary progress plot for DE calculations for product of 
nicotinamide and azelaic acid crystallisation for Np=35, K=0.99, F=0.2. 
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Figure 5.9.2.2:   Evolutionary progress plot for DE calculations for product of 
nicotinamide and azelaic acid crystallisation for Np=35, K=0.99, F=0.3. 
 
 
 
 
 
 
Figure 5.9.2.3:    Evolutionary progress plot for DE calculations for product of  
nicotinamide and azelaic acid crystallisation for Np=35, K=0.99, F=0.4. 
 
N=0.4 
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Figure 5.9.2.4:   Evolutionary progress plot for DE calculations for product of 
nicotinamide and azelaic acid crystallisation for Np=35, K=0.99, F=0.5. 
 
 
 
 
 
 
 
 
 
 
5.9.3 Crystal structure determination using Rietveld refinement 
 
Refinement of structure solution is carried out using the Rietveld
49
 profile refinement. 
The crystal structure determination is completed after a suitable structure solution was 
obtained from differential evolution technique. The refinement is carried out using 
GSAS
43
 & EXPGUI
61
 software suites. During refinement, the intramolecular bonds in 
molecular fragments are subjected to various bond length and bond angle restraints. 
The C-C and C-H bond lengths are restrained about 0.005Å and 0.001Å respectively 
and the bond angles are restrained about 120
°
 angle. The fitness of experimental and 
calculated diffraction patterns are compared point by point including selected profile 
parameters
19
. The lowest R-factor obtained for the structure solution of azelaic acid : 
nicotinamide (1:1) adduct is 14.6%. After the Rietveld refinement, the R-factor of 
crystal structure is further reduced to 11.6% (see figure 5.9.3.1).  
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Figure 5.9.3.1:    Rietveld refinement of the azelaic acid : nicotinamide (1:1) adduct. 
The green solid line shows the calculated intensities and the red crosses are observed 
intensities. The difference between the calculated and observed intesities is shown by 
pink line below. Reflection positions are also shown . 
 
For the application of global optimization technique (DE) in directs space methods, 
the conformational flexibility of a molecular model is defined by the variation of a 
number of torsion angles. The H atoms in the carboxylic acid group are ignored the 
structure solution process and the carboxylate treated as the symmetrical functional 
group that is not discriminated in powder structures. Nicotinamide is a 
crystallographically unsymmetrical molecule with one flexible amide functional 
group, and so would require two variables to define the conformational flexibility in 
the molecule. As the H atoms in NH2 group of the amide in nicotinamide are weak X-
ray scatterers (producing little intensity at high diffraction angle), they are ignored 
during the execution of the structure solution process reducing the calculation to one 
conformational variable. However, there is a strong possibility that the N and C atoms 
in the pyridine ring and the N and O atoms of the amide functional group may have 
alternate conformation from the structure solution, compared to the correct crystal 
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structure. This is due to the similar electron densities of the atoms. Hence a number of 
possible conformations of nicotinamide have been modelled by replacing the 
nicotinamide with all possible conformations and evaluated to determine which ones 
give accurate and sensible intermolecular synthons and motifs in the crystal structure 
(see figure 5.9.3.2).  
 
 
 
(a)                            (b)                              (c)           (d) 
Figure 5.9.3.2: Models of the nicotinamide molecule showing possible conformations 
of the pyridine ring in the structure (a) and (b) and the relative position of the amide 
group(c) and (d). 
 
Figure 5.9.3.3 shows the molecular arrangement in the crystal structure as it is 
obtained from the structure solution process. Possible synthons were connected 
manually generating heteromeric motifs between the amide and carboxylic acid 
moieties. The pyridine N atom is the best hydrogen bond acceptor whereas the 
carboxylic acid is the best hydrogen bond donor expected to form strong pyridine 
N
….
H-O hydrogen bonding between the nicotinamide and azelaic acid molecules. It is 
also expected that combination of co-crystal formers would form multiple 
intermolecular bonds rather than zero dimensional supramolecular blocks throughout 
the crystal structure.  
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Figure 5.9.3.3:     Projection on the [001] plane for the structural solution of the 
azelaic acid : nicotinamide (1:1) adduct. 
 
A possible conformation of nicotinamide with the pyridine ring flipped by a 180° 
angle with respect to the amide functional group gives molecular structure with both 
N atoms on the same side with respect to axis passing through the molecule (see 
figure 5.9.3.2 (a)). The possible intermolecular bonds are connected between the 
molecules producing pyridine N
….
H-O synthons and heteromeric motifs between 
amide and carboxylic acid moieties constructing one dimensional long continuous 
chain along on b-axis throughout the crystal structure. The intermolecular bonds 
shown in the below structure solution are possible, unless the carbonyl groups in the 
azelaic acid are on the opposite sides with respect to the central axis passing through 
the carbon chain (see figure 5.9.3.4). 
 
  
Figure 5.9.3.4: Project on the [001] plane for the structure solution of azelaic acid : 
nicotinamide (1:1) adduct. 
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 Another possible conformation of the nicotinamide molecule obtained with the amide 
functional group flipped 180° angle with respect to pyridine ring implies a molecular 
structure with both N atoms on the same side with respect to the axis passing through 
the molecule (see figure 5.9.3.2 (c)). The possible intermolecular molecular 
interactions are interpreted producing aromatic C-H
….
O=C synthons and heteromeric 
motifs between amide and carboxylic acid moieties (see figure 5.9.3.5). The high 
probability of forming strong hydrogen bonds between pyridine N and carboxylic acid 
functional groups rather than weak hydrogen bonds (C-H
….
O=C synthons) implies 
that this crystal structure would be very unlikely to be formed.  
 
Figure 5.9.3.5:     Project on the [001] plane for the structure solution of azelaic acid 
:  nicotinamide (1:1) adduct with swapped atoms. 
 
The conformation for nicotinamide molecule shown in figure 5.9.3.2 (d) was tried as 
another possibility in the crystal structure (see figure 5.9.3.6). The interpretation of 
possible intermolecular bonds in the structure solution produces pyridine N
...
H-O and 
N-H
...
O=C synthons and heteromeric motifs between amide and carboxylic acid 
moieties. Presence of strong hydrogen bonds between pyridine N and carboxylic acid 
functional groups and formation of maximum intermolecular bonds simultaneously 
satisfying stable conformations of molecular structures illustrates the formation of 
crystal structure with these specified intermolecular bonds would be more close to the 
correct crystal structure compared to the former possibilities (see figures 5.9.3.3-
5.9.3.6). 
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Figure 5.9.3.6:   Projection on the [001] plane for the crystal structure of azelaic acid 
: nicotinamide (1:1) adduct  showing  R
2
2
 (8) and  R
4
4
 (28) rings in the unit cell. 
 
The adduct is assumed to be in neutral cocrystal rather than salt form as it is not 
possible to distinguish the proton position by X-ray powder diffraction. The moieties 
between nicotinamide and azelaic acid formed with amino N9 at (1-x, 1-y, -½ ) act as 
hydrogen bond donors via H1A at (1-x, 1-y, -½+z) to O10 and N9 at (1-x, 1-y, -½+z) 
acts as hydrogen bond donors via H1B at (1-x, 1-y, -½+z ) to O21 at (1-x, 1-y, ½+z) 
produces R
4
4(28). O22 at (1-x, 1-y, -½+z) acts as a hydrogen bond donor via H22A at 
(x, y, z) to O2 at (x, y, y), and combined with N9-H1A---O10 produces R
2
2
 (8). The 
propagation of these hydrogen bonds produces C(14) spiral chains running through 
the unit cell can be observed. Four spiral chains running through the unit cell can be 
observed. Two spirals running along the (1, ½, z) and (½, 1, z) axes having opposite 
hand along (½, 0, -z) and (0, ½, -z) axes. O11 at (½-x, ½+y, -½+z) acts as a hydrogen 
bond donor via H11A at (½-x, ½+y, -½+z) to pyridine   N2 at (½-x, ½+y, -½+z) and 
this hydrogen bond links the C(14) spirals together leading to continuous three 
dimensional framework throughout the crystal structure (see figure 5.9.3.1). All these 
intermolecular bonds combines to form large ring R
8
8(60) and this ring is comprised 
with repetition of N9-H1A---O10 synthons for two times, O22-H22A---O2 for two 
times and O11-H11A---N6 for four times (see figure 5.9.3.6). From the extent of 
obtained crystal structure and IR spectral data, it is evident that the material obtained 
through the crystallisation of azelaic acid and nicotinamide (1:1 starting ratio) would 
be a co-crystal rather than a salt although not conclusively.  
RAJA SEKHAR VOGURI                                   RESULTS 
_____________________________________________________________________ 
 86 
 
 
Figure 5.9.3.7: ORTEP diagram of the azelaic acid : nicotinamide (1:1) adduct 
showing labelling of atoms and the interaction between the two former molecules. 
Thermal ellipsoids are drawn at the 50% probability level.  
 
 
 
 
Figure 5.9.3.8: Stereoview of azelaic acid : nicotinamide (1:1) adduct, showing R4
4
(8) 
and C(14) spiral molecular ladder along (1/2, 1, Z). 
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Table 5.9.3.1 
Summary of crystal data for azelaic acid and nicotinamide co-crystal obtained from 
PXRD. 
 
 
Empirical formula (C6H6N2O6):(C9H14O) 
Formula weight 306.32 
Cell setting, space group Monoclinic 
Z 4 
Radiation type Cu Kα1 
Temperature [K] 273 (2) 
λ[Å ] 1.54056 
Indexing  
Initial a[Å] 8.8816 
Initial b[Å] 36.7807 
Initial c[Å] 5.2585 
Initial α[°] 90 
Initial β[°] 90 
Initial γ[°] 90 
Structural solution 
Le bail Rwp 0.0916 
Le bail χ2 0.6759      
Elements 9 
K 0.99 
Best F 0.3 
Best Rwp 17.06 
Refinement 
Rwp 11.69 
χ2 2.545 
No. of reflections (Initial/final) 297/300 
No. of parameters  530 
No. of restraints 77 
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Final a (Å) 8.880 (19) 
Final b (Å) 36.788 (11) 
Final c (Å) 5.257 (14) 
Final α (°) 90 
Final β (°) 90 
Final γ (°) 90 
V (Å
3
) 1717.7 
 
Table 5.4.2 
 
Intermolecular hydrogen bond parameters [Å, °] in the adipic acid:nicotinamide (1:2) 
co-crystal. 
 
_____________________________________________________________________ 
D-H
...
A   d(D-H) d(H
...
A) d(D
...
A) <(DHA) 
_____________________________________________________________________ 
 N(9)-H(1A)
---
O(10)(i) 1.01  1.933  2.598  179.92 
N(9)-H(1B)---O(21)(i) 1.01  1.583  2.941  179.94 
O(22)-H(22A)---O(2)(i) 1.05  1.483  2.533  171.09 
O(11)-H(11A)---N(2)(ii) 1.01  1.754  2.811     ----- 
_____________________________________________________________________ 
(i) 1-x, 1-y, -½+z  (ii)  (½-x, ½+y, -½+z)  
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5.10 Azelaic and isonicotinamide 
 
Azelaic acid (see figure 2.2(g)) was crystallised with isonicotinamide using different 
solvents (methanol and ethanol) in a 1:1 starting molar ratio. Similar X-ray diffraction 
patterns for materials obtained from methanol and ethanol shows the formation of 
same new product obtained as a white crystalline solid although there may be small 
amount of azelaic acid also present. Solution mediated crystallisation was used for the 
synthesis (see figure 5.10.1). 
 
Figure 5.10.1: X-ray powder diffraction pattern for isonicotinamide and azelaic acid 
and product of crystallisation. 
 
From the integral values of different peak intensities for protons in different 
environments on azelaic acid and isonicotinamide obtained from NMR spectra, it is 
evident that the new material has a 1:1 stoichiometric ratio (see figure 5.10.2). 
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Figure 5.10.2: 
1
H NMR of azelaic acid and isonicotinamide and product of 
crystallisation using DMSO as solvent. 
1
H NMR 300MHz (DMSO-d6):  δ = 11.98(s, 
2H), 8.70(dd, 2H), 8.25(s, 1H), 7.76(dd, 2H), 7.73(s, 1H) 2.18(m, 4H), 1.47(m, 4H), 
1.23(m, 6H). 
 
The IR data for the crystallisation product (1:1) is compared to that from a mixture of 
the starting materials (figure 5.10.3). For a discussion of characteristic IR peaks of the 
starting materials, please see sections 5.2 and 5.6. The absence of characteristic high 
tones at 3000cm
-1
 for O-H bond stretching frequency for a carboxylic acid shows the 
involvement of the carboxylic acid group in intermolecular bonding. There are also 
indications of a potential broad band at ~2449cm
-1
 and hence the discrimination 
between neutral co-crystal and salt form is again not clear. 
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Figure 5.10.3: FTIR spectra for azelaic acid and isonicotinamide and product of 
crystallisation. 
 
Possible cell parameters were obtained by indexing the twenty most intense peaks in 
the powder X-ray diffraction pattern using the XFIT software. CRYSFIRE was used to 
index the selected peaks (see appendix K). Possible cell parameters were chosen for 
Le bail pattern decomposition on the basis of the stoichiometric ratio between the 
molecules obtained from NMR along with cell volume calculations and figure of 
merit (see table 8). The accuracy of unit cell parameters would be confirmed through 
Le bail pattern decomposition method (see figures 5.10.4).  The space group was 
assigned as P-1 as this gave the correct cell volume given a 1:1 stoichiometry (see 
table 5.10.1). The best fit between the experimental data (red) and simulated pattern 
(green) is quantified in terms of R-factor value (wRp) and χ2. The lowest R-factor and 
χ2 values obtained are 0.0975 and 67.62 respectively (see table 5.10.1).  
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Table  5.10.1 
 
Indexed and refined cell parameters obtained for the product of azelaic acid and 
nicotinamide: 
 
 
 
Figure of 
Merit 
a(Å) b(Å) c(Å) α(o) β(o) γ(o) 
Cell 
volume 
(Å3) 
Space 
group 
PXRD 
indexing 
13.76 9.074 18.950 5.471 95.863 102.70 89.682 912.995 P-1 
PXRD Le bail 
fit 
Rwp = 0.0975/ 
67.62 
9.074
6 
18.829 5.438 96.117 102.66 89.623 902.139 P-1 
   
 
 
Figure 5.10.4: The Le Bail profile fitting for the product of isonicotinamide and 
azelaic acid crystallisation (1:1) adduct.  
 
No further structural characterisation was carried out on this product. 
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5.11  Melting point alternations 
 
The phenomenon of melting point alternations in α,ω-alkanedicarboxlic acids was 
first established by Caspari in 1928
70
. Since then similar research has been done by 
research groups building various strategies based on molecular structures, packing 
motifs, crystal densities and packing fraction etc due to their significance in 
pharmaceutical industry
5, 21, 71, 72
. These theories could be applied to the selection of 
suitable former molecules to modify the physical properties of an API in the form of a 
pharmaceutical co-crystal. The melting point alternations in the new materials 
obtained in this project were investigated with the intention to observe the effect of 
former molecules on the physical properties of the new crystalline materials formed 
(see chart 5.11.1). From the results obtained, it is evident that the melting points are 
altered through co-crystallisation. The melting points of all the new materials fell in 
between the values of their corresponding former materials except for the products of 
malonic acid : nicotinamide (1:1 and 1:2). 
 
 
 
 
Nicotinamide (128°C) 
Oxalic acid (189°C) 
Malonic acid (134°C) 
Adipic acid (151°C) 
Pimelic acid (103°C) 
Suberic acid (142-144°C) 
Azelaic acid (106.5°C) 
Product (199-200°C) in 1:1 
ratio 
Product (94-95°C) in 1:1 ratio 
 
Product (124-125°C) in 2:1 
ratio 
 
Product (100-102°C) in 1:1 
ratio 
 
Product (115-117°C) in 1:1 
ratio 
 
Product (110-111°C) in 1:1 
ratio 
 
Product (96-97°C) in 2:1 ratio 
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Chart 5.11.1: Chart showing melting points of starting materials corresponding 
products of crystallisation. 
 
 
Isonicotinamide (156°C) 
 
 Suberic acid (103°C) 
 
Pimelic acid (103°C) 
 
Product (120°C) in 1:1 ratio 
 
Product (117°C) in 1:1 ratio 
 
RAJA SEKHAR VOGURI                                   RESULTS 
_____________________________________________________________________ 
 95 
Table 5.11.1 
 
Summary table of new materials (includes stoichiometries, status and corresponding 
starting materials). 
Dicarboxylic 
acids 
Former molecules Status 
Oxalic acid Nicotinamide 
Co-crystal or salt (1:1 and 1:2)-
inconclusive 
Malonic acid Nicotinamide 
Co-crystal rather than salt (1:1 and 
1:2)- inconclusive 
Succinic acid Nicotinamide Co-crystal or salt (1:1)- inconclusive 
Adipic acid Nicotinamide Co-crystal (1:2) 
Pimelic acid 
Nicotinamide 
Salt rather than co-crystal (1:1)- 
inconclusive 
Isonicotinamide 
Salt rather than co-crystal (1:1)- 
inconclusive 
Suberic acid 
Nicotinamide 
Co-crystal or salt (1:1 and 1:2)- 
inconclusive 
Isonicoitnamide Co-crystal or salt (1:1)- inconclusive 
Azelaic acid 
Nicotinamide 
Co-crystal rather than salt (1:1)- 
inconclusive 
Isonicotinamide Co-crystal or salt (1:1)- inconclusive 
RAJA SEKHAR VOGURI                           CONCLUSION 
_____________________________________________________________________ 
 96 
6. CONCLUSION 
 
The new co-crystal materials have been synthesized using both methanol and ethanol 
as solvents in different stoichiometric ratios using solvent drop grinding and solvent 
mediated crystallisation methods. In most cases, the same products were formed for 
different solvents showing no reliance on solvent interactions. All the starting 
materials were crystallized from different stoichiometric ratios (1:1, 1:2 and 2:1) but 
almost all products were obtained in a 1:1 stoichiometric ratio. The adipic acid : 
nicotinamide co-crystal was obtained only in a 1:2 stoichiometric ratio whereas a few 
other few materials were obtained in both 1:1 and 1:2 stoichiometries (oxalic acid, 
malonic acid and suberic acid : nicotinamide). Any synthesis with a 2:1 starting 
stoichiometric ratio resulted in either 1:1 or 1:2 products with a small quantity of 
excess starting materials. No products were obtained with a 2:1 stoichiometric ratio.  
 
The crystal structure of adipic acid : nicotinamide (1:2) was solved using single-
crystal X-ray diffraction and contains continuous hydrogen-bonded zigzag sheets 
running along the c-axis with no significant intermolecular bonds between the sheets. 
The crystal structure of azelaic acid : nicotinamide (1:1) was solved from X-ray 
powder diffraction data in which the molecules are arranged in the form of spiral 
chains running along the c-axis. These spirals are interconnected through 
intermolecular hydrogen bonds spreading into a three dimensional framework.  
 
The analysis of melting point alternations in all the new materials implies that the 
physical properties of the formers can be modified in the form of co-crystals. The 
melting point values of these new products falls between the values of the 
corresponding starting materials with no significant pattern observed with sequential 
increase in the methylene groups in the dicarboxylic acids. 
 
The former molecules of focus in this project have demonstrated that the 
complementary functional groups provide reliable synthons for the formation of 
hydrogen bonds between them. The crystal structure of adipic acid : nicotinamide 
contains (pyridine)N─acid and amide─amide motifs whereas crystal structure of 
azelaic acid:nicotinamide was found to contain (pyridine)N─acid and acid─amide 
motifs. In both cases, the formation of (pyridine)N─acid as a stronger intermolecular 
RAJA SEKHAR VOGURI                           CONCLUSION 
_____________________________________________________________________ 
 97 
bond is maintained. Comparatively, the acid─amide is stronger than the amide─amide 
intermolecular bond. But, the high quantity of nicotinamide in starting stoichiometries 
of adipic acid : nicotinamide (2:1) increases the availability of amide functional 
groups for intermolecular interactions leading to the formation amide-amide moieties 
rather than acid–amide moieties. Similarly, the equal starting stoichiometries of 
azelaic acid : nicotinamide (1:1) formed acid-amide moieties in the resulted crystal 
structure. 
 
Although this project has generated a significant number of adduct materials further 
work could be done to analyse the co-crystal properties such as dissolution, solubility 
and the behaviour of former materials towards co-crystallisation. The crystallisation 
of nicotinamide with succinic acid, pimelic acid, suberic acid and isonicotinamide 
with pimelic acid, suberic acid and azelaic acid needs to be investigated using 
different stoichiometries, different solvents and synthesis methods (see section 3.1 
and 3.2) to ensure whether the synthesis of materials showing polymorphic behaviour 
or alternative stoichiometry could be possible. 
 
The crystal structures of the new materials oxalic acid : nicotinamide (1:2), malonic 
acid : nicotinamide (1:1), suberic acid : isonicotinamide (1:2) and azelaic acid : 
isonicotinamide (1:1) need to be determined using PXRD or SXRD techniques. 
Although the crystal structures of adipic acid : nicotinamide (1:2) and azelaic : 
nicotinamide (1:1) were obtained from PXRD, there are difficulties in distinguishing 
groups (or atoms) with similar electron densities, such as the position of the 
heterocyclic N in the ring or the conformation of this amide group (see section 5.9.3). 
To overcome this limitation, synchrotron data could be used to ensure the correct 
crystal structures. Use of laboratory PXRD to determine the position of the proton in a 
salt (or a co-crystal) is impossible. But it may be possible that high quantity 
synchrotron PXRD can determine whether the product is a salt or a co-crystal. 
 
These results are also employed in a new project dealing with multi phase structural 
problems. The crystal structures throughout the project were solved from single phase 
powder diffraction data. The materials obtained throughout this project were 
crystallised from these different starting stoichiometries (1:1, 1:2 and 2:1) and the 
products  obtained from these different stoichiometric ratios could be either pure or 
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mixture of the new product with a quantity of one of the starting materials in excess. 
This multiphase powder diffraction data is being used to investigate the determination 
of crystal structures from such data. The crystal structures suberic acid : 
isonicotinamide (1:1) and pimelic acid : isonicotinamide (1:1) have now also been 
solved single crystal methods, but these results are not included in this thesis due to 
constraints of project time and report length. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________ 
The materials (oxalic acid (1:1), malonic acid (1:2), succinic acid (1:1), adipic acid 
(1:2), pimelic acid (1:1), suberic acid (1:1) and azelaic acid : nicotinamide (1:1)) 
synthesized in the current project were assumed to be unpublished relying on the 
rigorous search done using the Cambridge Structural Database (CSD). 
Unfortunately, the content had already been published on 4
th
 November 2008
73
 and 
the CSD had not been updated.  
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8. APPENDICES 
 
APPENDIX A 
   
 
X-ray diffraction patterns of nicotinamide and oxalic acid and products of 
crystallisation. 
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APPENDIX B 
 
X-ray diffraction patterns of nicotinamide and malonic acid and products of 
crystallisation. 
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APPENDIX C 
 
Cell parameters obtained from indexing the X-ray diffraction data of the product of 
nicotinamide and malonic acid using CRYSFIRE 
I20 Merit Volume V/V1 a b c alpha beta gamma 
20 23.61 492.533 1 10.444 10.277 5.121 96.095 103.878 67.383 
20 23.6 985.066 2 11.496 16.931 5.121 95.166 97.065 88.888 
20 13.29 493.9 1 10.277 10.463 5.122 103.726 84.193 112.604 
20 13.15 494.166 1 10.237 10.548 5.127 104.369 96.629 67.170 
20 10.18 537.039 1.09 10.231 10.242 5.569 93.668 96.070 67.787 
20 7.6 491.557 1 10.228 10.357 5.098 101.086 91.482 111.150 
20 7.05 535.364 1.09 11.139 10.184 5.552 93.585 113.385 108.467 
20 7.04 983.696 2 20.960 12.036 10.202 57.613 150.805 128.402 
20 6.1 1987.266 4.03 13.151 15.899 10.697 90.000 117.304 90.000 
20 6.1 1987.266 4.03 13.151 15.899 10.697 90.000 117.304 90.000 
20 6.1 1839.829 3.74 11.990 18.950 9.831 90.000 124.543 90.000 
20 6.1 1839.829 3.74 11.990 18.950 9.831 90.000 124.543 90.000 
20 5.8 1840.431 3.74 11.997 18.951 10.330 90.000 128.401 90.000 
20 5.8 1840.431 3.74 11.997 18.951 10.330 90.000 128.401 90.000 
20 5.8 1840.425 3.74 10.330 18.951 9.832 90.000 107.020 90.000 
20 5.8 1840.425 3.74 10.330 18.951 9.832 90.000 107.020 90.000 
20 5.69 505.23 1.03 10.320 10.702 5.240 71.749 97.794 113.160 
20 5.37 572.247 1.16 11.905 11.198 5.935 65.183 120.815 120.376 
20 5.3 3742.616 7.6 64.732 9.500 6.086 90.000 90.000 90.000 
20 5.3 3742.616 7.6 64.732 9.500 6.086 90.000 90.000 90.000 
20 5.2 1700.141 3.45 18.990 5.994 18.193 90.000 124.819 90.000 
20 5.2 1700.141 3.45 18.990 5.994 18.193 90.000 124.819 90.000 
20 5.1 1699.975 3.45 18.990 5.994 17.233 90.000 119.934 90.000 
20 5.1 1699.975 3.45 18.990 5.994 17.233 90.000 119.934 90.000 
20 5 2002.386 4.07 13.318 15.950 10.639 90.000 117.619 90.000 
20 5 2002.386 4.07 13.318 15.950 10.639 90.000 117.619 90.000 
20 5 1968.474 4 25.358 5.269 19.172 90.000 129.782 90.000 
20 5 1968.474 4 25.358 5.269 19.172 90.000 129.782 90.000 
20 4.9 4447.09 9.03 10.116 15.897 27.653 90.000 90.000 90.000 
20 4.69 3269.274 6.64 5.841 20.261 27.625 90.000 90.000 90.000 
20 2.85 580.837 1.18 11.696 5.293 9.982 74.467 100.636 99.478 
19 15 493.146 1 5.125 12.748 11.501 68.651 97.172 52.764 
19 12.78 582.583 1.18 10.198 10.309 6.045 97.400 94.752 67.675 
19 12.56 506.545 1.03 10.519 10.301 5.251 96.787 104.812 67.096 
19 12.56 506.545 1.03 10.519 10.301 5.251 96.787 104.812 67.096 
19 12.49 493.691 1 10.214 10.518 5.122 103.588 95.770 67.396 
19 12.48 506.393 1.03 10.234 10.566 5.254 104.621 96.846 67.148 
19 12.41 548.487 1.11 10.271 10.244 5.690 93.652 98.289 67.802 
19 11.09 643.512 1.31 10.761 12.776 5.330 103.124 100.243 64.905 
19 10.59 586.354 1.19 10.176 10.284 6.082 96.075 93.183 111.368 
19 10.59 586.354 1.19 10.176 10.284 6.082 96.075 93.183 111.368 
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19 10.39 616.297 1.25 10.670 10.387 6.396 100.333 107.729 66.159 
19 10.33 535.985 1.09 10.182 10.286 5.559 96.182 93.380 67.854 
19 10.04 630.418 1.28 10.351 10.693 6.553 106.979 101.746 65.928 
19 9.69 803.709 1.63 10.167 10.347 8.339 98.952 88.742 111.842 
19 9.31 647.134 1.31 10.179 10.423 6.711 101.240 87.139 112.050 
19 9.21 615.007 1.25 10.669 10.389 6.381 100.229 107.765 66.205 
19 9.19 1080.304 2.19 11.305 11.208 11.133 114.057 118.847 64.695 
19 9.13 647.605 1.31 10.179 10.429 6.715 101.299 87.133 112.062 
19 9.1 1398.93 2.84 11.575 13.571 10.788 86.940 117.674 109.991 
19 9.02 925.806 1.88 11.117 12.488 7.653 86.430 107.406 113.760 
19 8 1251.724 2.54 20.256 10.779 5.744 90.000 93.587 90.000 
19 8 1251.724 2.54 20.256 10.779 5.744 90.000 93.587 90.000 
19 7.4 1249.88 2.54 10.247 12.954 10.322 99.774 111.045 93.239 
19 5.7 1124.06 2.28 11.174 11.723 11.011 113.150 118.183 65.918 
19 5.4 1248.87 2.54 10.241 12.955 10.316 99.777 110.997 93.248 
19 4.8 1991.96 4.04 12.540 16.011 10.680 90.000 111.729 90.000 
18 19.45 491.727 1 10.187 10.499 5.102 103.195 86.168 112.201 
18 19.44 491.727 1 10.187 10.499 5.102 103.195 86.167 112.201 
18 12.97 491.603 1 10.428 10.249 5.100 86.057 102.982 112.210 
18 12.63 764.92 1.55 11.009 10.300 7.936 82.869 112.559 112.945 
18 12 492.823 1 5.123 12.672 11.493 59.167 82.922 53.026 
18 11.36 528.564 1.07 10.265 10.251 5.483 94.100 98.062 67.753 
18 9.29 1173.009 2.38 11.786 11.892 10.225 107.650 109.479 61.875 
18 8.57 1128.898 2.29 11.200 11.717 11.030 113.001 118.164 65.885 
18 8 1032.816 2.1 11.585 17.191 5.266 90.000 99.991 90.000 
18 8 1032.816 2.1 11.585 17.191 5.266 90.000 99.991 90.000 
18 8 1032.815 2.1 11.865 17.191 5.266 90.000 105.927 90.000 
18 8 1032.815 2.1 11.865 17.191 5.266 90.000 105.927 90.000 
18 7 1065.715 2.16 19.119 5.262 10.654 90.000 96.129 90.000 
18 7 1032.664 2.1 11.582 17.193 5.266 90.000 100.006 90.000 
18 7 1032.664 2.1 11.860 17.193 5.266 90.000 105.923 90.000 
18 6.5 2535.96 5.15 11.229 23.827 10.375 90.000 113.989 90.000 
17 20.07 713.501 1.45 10.173 10.223 7.401 91.020 91.797 111.883 
17 15.74 576.578 1.17 10.317 10.383 5.982 100.079 99.868 109.392 
17 11.72 634.563 1.29 10.414 10.790 6.582 108.729 102.349 65.496 
17 11.27 835.067 1.7 7.608 19.070 6.069 94.822 107.846 87.450 
17 10 1064.321 2.16 12.861 9.184 10.143 90.000 117.319 90.000 
17 10 1064.321 2.16 12.188 9.184 10.143 90.000 110.360 90.000 
17 9.99 539.656 1.1 10.201 10.342 5.599 98.565 95.218 67.618 
17 9.57 640.563 1.3 10.428 10.413 6.625 100.473 102.199 108.856 
17 9.49 646.161 1.31 10.150 10.401 6.707 100.387 89.684 111.591 
17 9.15 666.022 1.35 10.187 10.587 6.910 105.023 94.305 109.840 
17 9 1064.451 2.16 12.191 9.183 10.142 90.000 110.361 90.000 
17 8 1096.092 2.23 22.340 10.110 5.706 90.000 121.725 90.000 
17 7 1103.23 2.24 9.712 19.009 5.979 90.000 92.029 90.000 
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APPENDIX D 
 
X-ray diffraction patterns of nicotinamide and succinic acid and products of 
crystallisation. 
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APPENDIX E 
 
X-ray diffraction patterns of nicotinamide and adipic acid and products of 
crystallisation. 
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APPENDIX F 
 
data_2009src0657 
  
_audit_creation_method            SHELXL-97 
_chemical_name_systematic 
; 
 ? 
; 
_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          '2(C6 H6 N2 O), C6 H10 O4' 
_chemical_formula_sum 
 'C18 H22 N4 O6' 
_chemical_formula_weight          390.40 
  
loop_ 
 _atom_type_symbol 
 _atom_type_description 
 _atom_type_scat_dispersion_real 
 _atom_type_scat_dispersion_imag 
 _atom_type_scat_source 
 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0061   0.0033 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
  
_symmetry_cell_setting            Triclinic 
_symmetry_space_group_name_H-M    'P -1' 
  
loop_ 
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x, -y, -z' 
  
_cell_length_a                    5.0261(2) 
_cell_length_b                    5.4280(3) 
_cell_length_c                    16.8981(10) 
_cell_angle_alpha                 98.147(2) 
_cell_angle_beta                  91.072(3) 
_cell_angle_gamma                 90.588(3) 
_cell_volume                      456.24(4) 
_cell_formula_units_Z             1 
_cell_measurement_temperature     120(2) 
_cell_measurement_reflns_used     11377 
_cell_measurement_theta_min       2.91 
_cell_measurement_theta_max       27.48 
  
_exptl_crystal_description        'Cut Slab' 
_exptl_crystal_colour             Colourless 
_exptl_crystal_size_max           0.18 
_exptl_crystal_size_mid           0.16 
_exptl_crystal_size_min           0.08 
_exptl_crystal_density_meas       ? 
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_exptl_crystal_density_diffrn     1.421 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              206 
_exptl_absorpt_coefficient_mu     0.108 
_exptl_absorpt_correction_type    Multi-scan 
_exptl_absorpt_correction_T_min   0.9808 
_exptl_absorpt_correction_T_max   0.9914 
_exptl_absorpt_process_details   'SADABS 2007/2 (Sheldrick, G.M., 
2007)'  
 
_exptl_special_details 
; 
 ? 
; 
  
_diffrn_ambient_temperature        120(2) 
_diffrn_radiation_wavelength       0.71073 
_diffrn_radiation_type             MoK\a 
_diffrn_radiation_source          'Bruker-Nonius FR591 rotating 
anode' 
_diffrn_radiation_monochromator   '10cm confocal mirrors' 
_diffrn_measurement_device_type    
'Bruker-Nonius APEX II CCD camera on \k-goniostat' 
_diffrn_measurement_method        '\f & \w scans' 
_diffrn_detector_area_resol_mean  '4096x4096pixels / 62x62mm' 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             7324 
_diffrn_reflns_av_R_equivalents   0.0331 
_diffrn_reflns_av_sigmaI/netI     0.0301 
_diffrn_reflns_limit_h_min        -6 
_diffrn_reflns_limit_h_max        6 
_diffrn_reflns_limit_k_min        -7 
_diffrn_reflns_limit_k_max        7 
_diffrn_reflns_limit_l_min        -21 
_diffrn_reflns_limit_l_max        21 
_diffrn_reflns_theta_min          3.65 
_diffrn_reflns_theta_max          27.48 
_reflns_number_total              2058 
_reflns_number_gt                 1880 
_reflns_threshold_expression      >2\s(I) 
  
_computing_data_collection         
'COLLECT (Hooft, R.W.W., 1998)' 
_computing_cell_refinement         
'DENZO (Otwinowski & Minor, 1997) & COLLECT (Hooft, R.W.W., 
1998)' 
#Although determined using DirAx, the cell is refined in the HKL 
#package during data reduction 
_computing_data_reduction          
'DENZO (Otwinowski & Minor, 1997) & COLLECT (Hooft, R.W.W., 
1998)'  
_computing_structure_solution     'SHELXS-97 (Sheldrick, 2008)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 2008)' 
_computing_molecular_graphics     'Ortep-3 for Windows (Farrugia, 
1997)' 
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_computing_publication_material   'WinGX (Farrugia, 1999)' 
 
  
_refine_special_details 
; 
 Refinement of F^2^ against ALL reflections.  The weighted R-
factor wR and 
 goodness of fit S are based on F^2^, conventional R-factors R 
are based 
 on F, with F set to zero for negative F^2^. The threshold 
expression of 
 F^2^ > 2\s(F^2^) is used only for calculating R-factors(gt) etc. 
and is 
 not relevant to the choice of reflections for refinement.  R-
factors based 
 on F^2^ are statistically about twice as large as those based on 
F, and R- 
 factors based on ALL data will be even larger. 
; 
  
_refine_ls_structure_factor_coef  Fsqd 
_refine_ls_matrix_type            full 
_refine_ls_weighting_scheme       calc 
_refine_ls_weighting_details 
 'calc w=1/[\s^2^(Fo^2^)+(0.0611P)^2^+0.2714P] where 
P=(Fo^2^+2Fc^2^)/3' 
_atom_sites_solution_primary      direct 
_atom_sites_solution_secondary    difmap 
_atom_sites_solution_hydrogens    geom 
_refine_ls_hydrogen_treatment     constr 
_refine_ls_extinction_method      none 
_refine_ls_extinction_coef        ? 
_refine_ls_number_reflns          2058 
_refine_ls_number_parameters      128 
_refine_ls_number_restraints      0 
_refine_ls_R_factor_all           0.0509 
_refine_ls_R_factor_gt            0.0468 
_refine_ls_wR_factor_ref          0.1327 
_refine_ls_wR_factor_gt           0.1294 
_refine_ls_goodness_of_fit_ref    1.115 
_refine_ls_restrained_S_all       1.115 
_refine_ls_shift/su_max           0.000 
_refine_ls_shift/su_mean          0.000 
  
loop_ 
 _atom_site_label 
 _atom_site_type_symbol 
 _atom_site_fract_x 
 _atom_site_fract_y 
 _atom_site_fract_z 
 _atom_site_U_iso_or_equiv 
 _atom_site_adp_type 
 _atom_site_occupancy 
 _atom_site_symmetry_multiplicity 
 _atom_site_calc_flag 
 _atom_site_refinement_flags 
 _atom_site_disorder_assembly 
 _atom_site_disorder_group 
RAJA SEKHAR VOGURI                            APPENDICES 
_____________________________________________________________________ 
 108 
C1 C 1.0734(3) 0.5734(3) 0.14120(9) 0.0176(3) Uani 1 1 d . . . 
C2 C 1.2755(3) 0.3983(3) 0.13776(9) 0.0199(3) Uani 1 1 d . . . 
H2 H 1.3984 0.3828 0.0954 0.024 Uiso 1 1 calc R . . 
C3 C 1.2941(3) 0.2470(3) 0.19721(9) 0.0212(3) Uani 1 1 d . . . 
H3 H 1.4295 0.1258 0.1961 0.025 Uiso 1 1 calc R . . 
C4 C 1.1118(3) 0.2758(3) 0.25831(9) 0.0216(3) Uani 1 1 d . . . 
H4 H 1.1241 0.1708 0.2987 0.026 Uiso 1 1 calc R . . 
C5 C 1.0321(3) 0.7411(3) 0.07924(9) 0.0179(3) Uani 1 1 d . . . 
C6 C 0.9011(3) 0.5912(3) 0.20542(9) 0.0190(3) Uani 1 1 d . . . 
H6 H 0.7650 0.7121 0.2085 0.023 Uiso 1 1 calc R . . 
N1 N 0.9189(3) 0.4457(3) 0.26276(8) 0.0212(3) Uani 1 1 d . . . 
N2 N 1.2423(3) 0.7897(2) 0.03675(8) 0.0199(3) Uani 1 1 d . . . 
H2A H 1.2256 0.8862 -0.0007 0.024 Uiso 1 1 calc R . . 
H2B H 1.3977 0.7252 0.0461 0.024 Uiso 1 1 calc R . . 
O1 O 0.8084(2) 0.8278(2) 0.06822(7) 0.0225(3) Uani 1 1 d . . . 
C7 C 0.4229(3) 0.7131(3) 0.38225(9) 0.0195(3) Uani 1 1 d . . . 
C8 C 0.0787(3) 0.9849(3) 0.46138(9) 0.0203(3) Uani 1 1 d . . . 
H8A H -0.0455 0.9829 0.4151 0.024 Uiso 1 1 calc R . . 
H8B H 0.2020 1.1287 0.4620 0.024 Uiso 1 1 calc R . . 
C9 C 0.2371(3) 0.7453(3) 0.45183(9) 0.0214(3) Uani 1 1 d . . . 
H9A H 0.3427 0.7396 0.5016 0.026 Uiso 1 1 calc R . . 
H9B H 0.1105 0.6026 0.4456 0.026 Uiso 1 1 calc R . . 
O3 O 0.4299(2) 0.8441(2) 0.32982(7) 0.0266(3) Uani 1 1 d . . . 
O4 O 0.5799(2) 0.5186(2) 0.38467(7) 0.0242(3) Uani 1 1 d . . . 
H4A H 0.6809 0.5042 0.3453 0.036 Uiso 1 1 calc R . . 
  
loop_ 
 _atom_site_aniso_label 
 _atom_site_aniso_U_11 
 _atom_site_aniso_U_22 
 _atom_site_aniso_U_33 
 _atom_site_aniso_U_23 
 _atom_site_aniso_U_13 
 _atom_site_aniso_U_12 
C1 0.0162(7) 0.0196(7) 0.0171(7) 0.0039(5) -0.0017(5) -0.0001(5) 
C2 0.0188(7) 0.0223(7) 0.0184(7) 0.0023(6) 0.0013(5) 0.0026(6) 
C3 0.0219(7) 0.0201(7) 0.0216(7) 0.0030(6) -0.0026(6) 0.0050(6) 
C4 0.0252(8) 0.0209(7) 0.0198(7) 0.0072(6) -0.0022(6) 0.0018(6) 
C5 0.0174(7) 0.0191(7) 0.0171(7) 0.0030(5) -0.0025(5) -0.0005(5) 
C6 0.0184(7) 0.0197(7) 0.0196(7) 0.0052(6) -0.0009(5) 0.0022(5) 
N1 0.0216(7) 0.0238(7) 0.0195(6) 0.0071(5) 0.0012(5) 0.0034(5) 
N2 0.0174(6) 0.0246(7) 0.0196(6) 0.0093(5) 0.0006(5) 0.0031(5) 
O1 0.0160(5) 0.0283(6) 0.0257(6) 0.0127(5) -0.0006(4) 0.0021(4) 
C7 0.0195(7) 0.0209(7) 0.0185(7) 0.0044(6) -0.0008(5) 0.0018(6) 
C8 0.0212(7) 0.0216(8) 0.0193(7) 0.0064(6) 0.0012(6) 0.0031(6) 
C9 0.0230(8) 0.0225(8) 0.0199(7) 0.0070(6) 0.0026(6) 0.0044(6) 
O3 0.0298(6) 0.0283(6) 0.0242(6) 0.0118(5) 0.0072(5) 0.0086(5) 
O4 0.0261(6) 0.0282(6) 0.0205(6) 0.0096(5) 0.0061(4) 0.0103(5) 
  
_geom_special_details 
; 
 All s.u.'s (except the s.u. in the dihedral angle between two 
l.s. planes) 
 are estimated using the full covariance matrix.  The cell s.u.'s 
are taken 
 into account individually in the estimation of s.u.'s in 
distances, angles 
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 and torsion angles; correlations between s.u.'s in cell 
parameters are only 
 used when they are defined by crystal symmetry.  An approximate 
(isotropic) 
 treatment of cell s.u.'s is used for estimating s.u.'s involving 
l.s. planes. 
; 
  
loop_ 
 _geom_bond_atom_site_label_1 
 _geom_bond_atom_site_label_2 
 _geom_bond_distance 
 _geom_bond_site_symmetry_2 
 _geom_bond_publ_flag 
C1 C6 1.394(2) . ? 
C1 C2 1.395(2) . ? 
C1 C5 1.494(2) . ? 
C2 C3 1.387(2) . ? 
C2 H2 0.9500 . ? 
C3 C4 1.386(2) . ? 
C3 H3 0.9500 . ? 
C4 N1 1.341(2) . ? 
C4 H4 0.9500 . ? 
C5 O1 1.2438(18) . ? 
C5 N2 1.3333(19) . ? 
C6 N1 1.3360(19) . ? 
C6 H6 0.9500 . ? 
N2 H2A 0.8800 . ? 
N2 H2B 0.8800 . ? 
C7 O3 1.2130(19) . ? 
C7 O4 1.3291(18) . ? 
C7 C9 1.507(2) . ? 
C8 C9 1.522(2) . ? 
C8 C8 1.529(3) 2_576 ? 
C8 H8A 0.9900 . ? 
C8 H8B 0.9900 . ? 
C9 H9A 0.9900 . ? 
C9 H9B 0.9900 . ? 
O4 H4A 0.8400 . ? 
  
loop_ 
 _geom_angle_atom_site_label_1 
 _geom_angle_atom_site_label_2 
 _geom_angle_atom_site_label_3 
 _geom_angle 
 _geom_angle_site_symmetry_1 
 _geom_angle_site_symmetry_3 
 _geom_angle_publ_flag 
C6 C1 C2 118.17(14) . . ? 
C6 C1 C5 118.63(13) . . ? 
C2 C1 C5 123.19(14) . . ? 
C3 C2 C1 118.95(14) . . ? 
C3 C2 H2 120.5 . . ? 
C1 C2 H2 120.5 . . ? 
C4 C3 C2 118.89(14) . . ? 
C4 C3 H3 120.6 . . ? 
C2 C3 H3 120.6 . . ? 
N1 C4 C3 122.65(14) . . ? 
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N1 C4 H4 118.7 . . ? 
C3 C4 H4 118.7 . . ? 
O1 C5 N2 122.38(14) . . ? 
O1 C5 C1 120.36(13) . . ? 
N2 C5 C1 117.25(13) . . ? 
N1 C6 C1 122.94(14) . . ? 
N1 C6 H6 118.5 . . ? 
C1 C6 H6 118.5 . . ? 
C6 N1 C4 118.38(13) . . ? 
C5 N2 H2A 120.0 . . ? 
C5 N2 H2B 120.0 . . ? 
H2A N2 H2B 120.0 . . ? 
O3 C7 O4 123.44(14) . . ? 
O3 C7 C9 125.28(14) . . ? 
O4 C7 C9 111.27(13) . . ? 
C9 C8 C8 111.24(16) . 2_576 ? 
C9 C8 H8A 109.4 . . ? 
C8 C8 H8A 109.4 2_576 . ? 
C9 C8 H8B 109.4 . . ? 
C8 C8 H8B 109.4 2_576 . ? 
H8A C8 H8B 108.0 . . ? 
C7 C9 C8 115.12(13) . . ? 
C7 C9 H9A 108.5 . . ? 
C8 C9 H9A 108.5 . . ? 
C7 C9 H9B 108.5 . . ? 
C8 C9 H9B 108.5 . . ? 
H9A C9 H9B 107.5 . . ? 
C7 O4 H4A 109.5 . . ? 
  
loop_ 
 _geom_torsion_atom_site_label_1 
 _geom_torsion_atom_site_label_2 
 _geom_torsion_atom_site_label_3 
 _geom_torsion_atom_site_label_4 
 _geom_torsion 
 _geom_torsion_site_symmetry_1 
 _geom_torsion_site_symmetry_2 
 _geom_torsion_site_symmetry_3 
 _geom_torsion_site_symmetry_4 
 _geom_torsion_publ_flag 
C6 C1 C2 C3 1.0(2) . . . . ? 
C5 C1 C2 C3 -178.53(14) . . . . ? 
C1 C2 C3 C4 -0.3(2) . . . . ? 
C2 C3 C4 N1 -0.6(2) . . . . ? 
C6 C1 C5 O1 -24.8(2) . . . . ? 
C2 C1 C5 O1 154.72(16) . . . . ? 
C6 C1 C5 N2 155.83(14) . . . . ? 
C2 C1 C5 N2 -24.6(2) . . . . ? 
C2 C1 C6 N1 -1.0(2) . . . . ? 
C5 C1 C6 N1 178.55(13) . . . . ? 
C1 C6 N1 C4 0.2(2) . . . . ? 
C3 C4 N1 C6 0.6(2) . . . . ? 
O3 C7 C9 C8 -9.5(2) . . . . ? 
O4 C7 C9 C8 171.17(13) . . . . ? 
C8 C8 C9 C7 -173.39(16) 2_576 . . . ? 
  
loop_ 
 _geom_hbond_atom_site_label_D 
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 _geom_hbond_atom_site_label_H 
 _geom_hbond_atom_site_label_A 
 _geom_hbond_distance_DH 
 _geom_hbond_distance_HA 
 _geom_hbond_distance_DA 
 _geom_hbond_angle_DHA 
 _geom_hbond_site_symmetry_A 
N2 H2A O1  0.88 2.06 2.9260(16) 167.9 2_775 
N2 H2B O1  0.88 2.14 2.8851(17) 141.4 1_655 
O4 H4A N1  0.84 1.85 2.6865(17) 174.2 . 
  
_diffrn_measured_fraction_theta_max    0.985 
_diffrn_reflns_theta_full              27.48 
_diffrn_measured_fraction_theta_full   0.985 
_refine_diff_density_max    0.340 
_refine_diff_density_min   -0.284 
_refine_diff_density_rms    0.059 
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APPENDIX G 
 
Atomic coordinates and equivalent isotropic displacement parameters (Å2x 103) for 
adipic acid and nicotinamide co-crystal.  U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 10734(3) 5734(3) 1412(1) 18(1) 
C(2) 12755(3) 3983(3) 1378(1) 20(1) 
C(3) 12941(3) 2470(3) 1972(1) 21(1) 
C(4) 11118(3) 2758(3) 2583(1) 22(1) 
C(5) 10321(3) 7411(3) 792(1) 18(1) 
C(6) 9011(3) 5912(3) 2054(1) 19(1) 
N(1) 9189(3) 4457(3) 2628(1) 21(1) 
N(2) 12423(3) 7897(2) 368(1) 20(1) 
O(1) 8084(2) 8278(2) 682(1) 23(1) 
C(7) 4229(3) 7131(3) 3823(1) 20(1) 
C(8) 787(3) 9849(3) 4614(1) 20(1) 
C(9) 2371(3) 7453(3) 4518(1) 21(1) 
O(3) 4299(2) 8441(2) 3298(1) 27(1) 
O(4) 5799(2) 5186(2) 3847(1) 24(1) 
________________________________________________________________________________ 
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APPENDIX H 
 
Standard bond lengths [Ǻ] and bond angles [˚] for the intra-molecular bonds in adipic 
acid : nicotinamide (1:2) co-crystal. 
_____________________________________________________________________ 
 d   d 
_____________________________________________________________________ 
C(1)-C(2) 1.380 C(7)-O(4) 1.308  
C(2)-C(3) 1.379 C(7)-O(3)  1.214 
C(3)-C(4) 1.379 C(7)-C(9)  1.502 
C(4)-N(1) 1.337 C(9)-C(8)  1.538 
C(6)-C(1) 1.380 C(8)-C(8)_i  1.542 
N(1)-C(6) 1.337 C(8)-H  1.092 
C(1)-C(5) 1.504 C(9)-H  1.092 
C(5)-O(1) 1.226  
C(5)-N(2) 1.325 
N(2)-H(2A) 0.88 
N(2)-H(2B) 0.88 
C(ar)-H 1.083 
C6 C1 C2  118.17 
C6 C1 C5    118.63 
C2 C1 C5    123.19 
C3 C2 C1    118.95 
C3 C2 H2    120.5 
C1 C2 H2    120.5  
C4 C3 C2    118.89 
C4 C3 H3    120.6  
C2 C3 H3    120.6  
N1 C4 C3    122.65 
N1 C4 H4    118.7  
C3 C4 H4    118.7 
O1 C5 N2    122.38 
O1 C5 C1    120.36 
N2 C5 C1    117.25 
N1 C6 C1    122.94 
N1 C6 H6    118.5  
C1 C6 H6    118.5  
C6 N1 C4    118.38 
  
C5 N2 H2A    120.0  
C5 N2 H2B    120.0  
H2A N2 H2B    120.0 
O3 C7 O4    123.44 
O3 C7 C9    125.28 
O4 C7 C9    111.27 
C9 C8 C8    111.24 
C9 C8 H8A    109.4  
C8 C8 H8A    109.4  
C9 C8 H8B    109.4  
C8 C8 H8B    109.4  
H8A C8 H8B    108.0  
C7 C9 C8    115.12 
C7 C9 H9A    108.5  
C8 C9 H9A    108.5  
C7 C9 H9B    108.5  
C8 C9 H9B    108.5  
H9A C9 H9B    107.5  
C7 O4 H4A    109.5  
 
________________________________________________________________________________ 
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APPENDIX I 
 
Cell parameters obtained from indexing the X-ray diffraction data of the product of 
nicotinamide and adipic acid using CRYSFIRE. 
 
I20 Merit Volume V/V1 a b c α β γ 
20 22.4 832.42 1 8.91 17.35 5.56 95.08 99.03 99.56 
20 20.4 832.61 1 8.91 17.35 5.56 95.08 99.03 99.56 
20 18.48 836.11 1 8.92 17.38 5.57 95.09 99.03 99.57 
20 8.43 1663.73 2 17.77 18.22 5.55 99.17 98.35 70.10 
20 7 484.14 0.58 5.14 5.84 18.82 70.20 83.40 109.69 
20 6.5 1728.14 2.08 17.13 9.22 11.00 90 96.72 90 
20 6.5 1728.14 2.08 17.13 9.22 11.00 90 96.72 90 
20 6.5 1728.14 2.08 19.25 9.22 11.00 90 117.87 90 
20 6.5 1728.14 2.08 19.25 9.22 11.00 90 117.87 90 
20 5.7 3960.87 4.76 19.32 35.78 5.73 90 91.87 90 
20 5.7 3502.25 4.21 30.76 20.39 5.58 90 92.09 90 
20 5.1 1939.82 2.33 19.64 5.77 18.86 90 114.94 90 
20 5.1 1939.82 2.33 19.64 5.77 18.86 90 114.94 90 
20 5.1 1930.80 2.32 27.50 4.09 17.49 90 101.75 90 
20 5.1 1930.80 2.32 27.50 4.09 17.49 90 101.75 90 
20 5.1 1929.98 2.32 29.43 4.09 17.49 90 113.83 90 
20 5.1 1929.98 2.32 29.43 4.09 17.49 90 113.83 90 
19 57.61 471.88 0.57 5.50 17.12 5.039 90.16 90.67 96.75 
19 9.63 822.23 0.99 8.83 17.31 5.57 95.34 99.69 99.27 
19 8 769.19 0.92 5.54 8.16 22.56 121.17 70.85 82.83 
19 8 769.19 0.92 5.54 8.16 22.56 121.17 70.85 82.83 
19 8 769.19 0.92 5.54 8.16 19.62 100.31 64.59 82.83 
19 6 2098.44 2.52 22.10 7.09 17.23 90 129.13 90 
19 6 2098.44 2.52 22.10 7.09 17.23 90 129.13 90 
18 9.1 1059.54 1.27 8.81 17.20 7.08 91.19 90.39 99.46 
18 9 991.61 1.19 17.11 5.29 11.00 90 96.72 90 
18 8 1529.03 1.84 17.49 5.46 16.28 90 101.24 90 
18 6 1510.18 1.81 22.67 5.29 17.26 90 133.26 90 
18 6 1158.03 1.39 17.18 10.17 6.64 90 94.84 90 
18 6 1158.03 1.39 17.18 10.17 6.64 90 94.84 90 
18 6 1158.03 1.39 17.18 10.17 6.64 90 94.84 90 
18 6 1158.03 1.39 17.89 10.17 6.64 90 106.87 90 
18 6 1064.83 1.28 17.40 7.07 8.76 90 99.66 90 
18 6 748.35 0.9 5.58 7.93 18.18 108.41 86.57 80.57 
18 6 748.35 0.9 5.58 7.93 17.51 94.17 79.47 80.57 
17 13.25 649.47 0.78 6.96 17.12 5.75 94.63 107.01 95.24 
17 11.15 651.17 0.78 7.03 17.06 5.75 93.73 107.52 96.57 
17 11 1235.94 1.48 17.30 6.53 11.00 90 96.46 90 
17 11 1235.94 1.48 19.43 6.53 11.00 90 117.76 90 
17 11 1235.94 1.48 19.43 6.53 11.00 90 117.76 90 
17 11 624.42 0.75 6.65 8.80 21.39 94.11 115.47 38.65 
17 10.47 773.57 0.93 7.89 17.16 6.10 93.61 108.78 81.43 
17 9 484.42 0.58 5.13 6.33 18.82 66.39 83.54 60.31 
17 9 484.42 0.58 5.13 6.33 20.71 56.36 69.37 60.31 
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17 9 484.42 0.58 5.13 5.85 20.71 73.09 69.37 109.90 
17 7 1158.66 1.39 20.85 10.17 6.64 90 124.73 90 
17 6 1502.64 1.81 17.26 7.97 11.00 90 96.88 90 
17 6 1502.64 1.81 17.26 7.97 11.00 90 96.88 90 
17 6 1323.31 1.59 22.67 10.84 5.46 90 99.92 90 
17 6 1323.31 1.59 22.38 10.84 5.46 90 93.98 90 
16 12.04 831.04 1 8.91 17.28 5.56 94.84 99.13 99.18 
16 9.45 1029.64 1.24 10.97 17.52 5.51 95.85 93.92 101.41 
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APPENDIX J 
 
 
 
X-ray diffraction patterns of nicotinamide and suberic acid and products of 
crystallisation. 
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APPENDIX K 
  
X-ray diffraction patterns of nicotinamide and azelaic acid and products of 
crystallisation. 
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APPENDIX L  
 
Cell parameters obtained from indexing of powder X-ray diffraction data the product 
of nicotinamide and azelaic acid crystallisation using CRYFIRE. 
I20 Merit Volume a b c α Β γ 
20 20 1665.95 8.796 36.3453 5.2111 90 90 90 
20 19.94 1672.95 8.8082 36.4064 5.217 90 90 90 
20 18.5 1674.22 37.5154 5.2155 8.8013 90 103.53 90 
20 18.3 1673.07 10.2441 36.3893 5.2178 90 120.66 90 
20 16.8 1675.46 10.2411 36.4655 5.2164 90 120.67 90 
20 16.4 1675.45 8.8082 36.4662 5.2162 90 89.95 90 
20 16.3 1673.89 8.8103 36.4272 5.2157 90 90.041 90 
20 16.3 1673.72 36.4317 8.8089 5.2154 90 90 90 
20 14.4 1676.63 36.8675 8.8054 5.2187 90 98.25 90 
20 14.4 1676.62 37.9298 8.8054 5.2187 90 105.86 90 
20 13.2 1675.38 37.5177 5.2149 8.8085 90 103.55 90 
20 13.2 1675.38 37.5177 5.2149 8.8085 90 103.55 90 
20 12.7 1674.03 42.005 8.8103 5.2118 90 119.78 90 
20 12.3 1671.47 37.4615 5.2144 8.7978 90 103.44 90 
20 12.3 1671.47 37.4615 5.2144 8.7978 90 103.44 90 
20 12.2 1676.21 37.5089 5.2156 8.8117 90 103.5 90 
20 12.2 1675.81 37.5118 5.2157 8.8101 90 103.53 90 
20 12.2 1675.56 36.4697 5.2157 8.8088 90 89.97 90 
20 12.1 1676.28 36.4749 5.2153 8.812 90 89.90 90 
20 12.1 1676.15 39.6826 8.8086 5.2142 90 113.12 90 
20 12 1676.13 36.8571 8.8085 5.2141 90 98.043 90 
20 11.9 1677.49 37.9729 8.8078 5.2202 90 106.09 90 
20 11.9 1671.01 8.8062 36.3877 5.2148 90 90 90 
20 11.7 1678.51 36.5093 8.806 5.2209 90 89.84 90 
20 11.2 1676.19 42.013 8.8086 5.2122 90 119.65 90 
20 10.7 1678.49 44.9438 8.8081 5.2203 90 125.68 90 
20 10.3 1678.51 36.8579 8.8082 5.2205 90 97.96 90 
20 10 1678.39 42.1087 8.8083 5.2208 90 119.91 90 
20 10 1676.49 37.9467 8.8088 5.2144 90 105.87 90 
20 9.9 1678.39 37.9294 8.8083 5.2208 90 105.79 90 
20 9 1679.94 39.7925 8.8082 5.2244 90 113.44 90 
20 7.6 1678.57 44.9136 8.8086 5.2196 90 125.62 90 
20 5.3 1672.91 36.5505 8.7906 5.2067 90 90.11 90 
20 5.1 1684.42 5.2162 36.4255 8.8665 90.94 90.19 89.99 
19 11.07 1707.09 9.7276 18.3036 9.6306 93.57 94.06 89.74 
19 11 415.47 5.2132 8.7515 9.3868 101.41 81.80 91.04 
19 10.47 415.20 8.7497 9.3792 5.2144 98.19 88.95 101.37 
19 9.95 1951.64 11.1164 18.4378 10.5496 96.06 114.38 83.18 
19 8 1305.46 16.7012 9.1203 9.6736 90 117.62 90 
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APPENDIX M 
Atomic coordinates and equivalent isotropic displacement parameters (Å2x 103) for azelaic 
acid and nicotinamide co-crystal.   
_____________________________________________________________________ 
 x y z  
_____________________________________________________________________ 
N1 C 0.5593 0.1153 0.5964 
O2 O 0.545(4) 0.8012(8) 1.028(5) 
C3 C 0.6482(34) 0.7561(6) 0.736(6) 
C4 C 0.590(4) 0.7269(7) 0.867(7) 
C5 C 0.724(4) 0.6876(7) 0.584(7) 
N6 N 0.623(5) 0.6922(6) 0.783(6) 
C7 C 0.7935(28) 0.7166(9) 0.487(7) 
C8 C 0.7348(29) 0.7497(7) 0.523(5) 
C9 H 0.5355 0.1691 0.6618 
O10 O 0.4794 0.1145 0.4099 
O11 O 0.5812 0.1452 0.7423 
C12 C 0.6499 0.0836 0.7005 
C13 C 0.6519 0.0505 0.5222 
C14 C 0.7444 0.0188 0.6324 
C15 C 0.7481 -0.014 0.451 
C16 C 0.8383 -0.046 0.5606 
C17 C 0.8401 -0.0787 0.3784 
C18 C 0.9267 -0.1437 0.3119 
C20 C 0.9294 -0.1109 0.4874 
C21 C 0.603(6) 0.7942(6) 0.805(5) 
O22 O 1.0118 -0.1372 0.1031 
O23 O 0.8602 -0.1718 0.3523 
H11A H 0.5951 0.8421 0.7451 
H1A H 0.7219 0.8229 0.5398 
H1B N 0.634(4) 0.8195(7) 0.659(5) 
____________________________________________________________________ 
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APPENDIX N 
Cell parameters obtained from indexing powder X-ray diffraction data of the product of 
isonicotinamide and azelaic acid crystallisation using CRYSFIRE. 
 
I20 Merit Volume a b c Α β γ 
20 9.95 929.60 9.0847 19.016 5.5755 97.222 103.341 89.319 
20 9.93 929.60 9.0847 19.016 5.5755 97.222 103.341 89.319 
20 9.32 913.02 8.9081 19.0293 5.4737 97.789 96.631 88.133 
20 9.29 1010.99 10.0272 11.2532 10.2212 111.582 103.387 97.953 
20 9.07 906.50 9.0409 18.9782 5.4318 96.127 101.925 89.757 
20 5.7 1745.79 18.9525 5.227 17.6234 90 90.494 90 
20 5.7 1745.79 18.9525 5.227 17.6234 90 90.494 90 
20 5.6 1313.11 10.5788 14.1659 9.9861 101.837 116.296 84.786 
20 5.1 4983.45 56.2239 17.5906 5.0388 90 90 90 
20 5.1 4983.45 56.2239 17.5906 5.0388 90 90 90 
19 16.93 835.90 8.8471 18.8571 5.0115 90.283 90.588 89.005 
19 16.65 835.85 8.8476 18.8548 5.0116 90.269 90.592 89.012 
19 13.76 912.99 9.0748 18.9507 5.4715 95.863 102.7 89.682 
19 13.52 1123.69 10.3198 11.5533 10.3563 109.295 103.535 92.309 
19 11.54 839.71 9.8002 10.7654 10.0066 117.562 114.924 71.822 
19 10.45 895.79 8.868 18.9382 5.3699 95.437 93.689 90.609 
19 10.03 883.10 9.0786 18.8628 5.2975 91.514 103.109 88.708 
19 9.44 1582.12 9.4867 18.8602 9.0786 90.441 102.866 92.243 
19 9.18 1249.99 9.147 18.9621 7.493 95.654 104.839 87.592 
19 7 1005.08 11.1774 11.5446 13.8349 52.092 132.544 124.066 
19 7 857.19 4.9708 10.6779 18.3095 82.468 87.589 62.86 
19 7 857.19 4.9708 9.5027 18.7694 82.819 77.068 89.397 
19 7 857.19 4.9708 9.5027 18.3095 82.803 87.589 90.603 
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